Stockwinners Market Radar for November 06, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:18 EST Cathie Wood's ARK Investment bought 221K shares of Recursion Pharmaceuticals

20:17 EST Cathie Wood's ARK Investment bought 369K shares of PacBio today

19:02 EST Bell to cut CapEx by over C$1B in 2024-2025 - Bell announced its intention to reduce capital expenditures by over C$1B in 2024-25, including a minimum of C$500M to C$600M in 2024, money the company had planned to invest in bringing high-speed fibre Internet to hundreds of thousands of additional homes and businesses in rural, suburban and urban communities. This reduction is in addition to Bell decreasing its 2023 capital expenditure budget by C$100M in anticipation of the CRTC decision to unrelentingly pursue wholesale access at the expense of critical network investment. Bell's fibre network is now available to over seven million homes and businesses. Prior to the CRTC's decision, Bell's near-term plan was to build high-speed fibre to nine million locations by the end of 2025. Bell will now re-consider pending builds in all communities where it had planned to expand, and will reduce its 2025 build target from nine million to 8.3M locations.

18:53 EST Costco exec sells $2.51M in common stock - In a regulatory filing, Costco disclosed that its Senior EVP sold 4.5K shares of common stock on November 3rd in a total transaction size of $2.51M.

18:22 EST Hecla Mining lowers 2023 silver output view to 14.4-14.8M oz from 14.5-15.5M oz - Backs 2024 silver output view at 17.5-18.5M oz and 2025 view at 18.5-20.0M oz.

18:21 EST Carvana CEO: We're on the right path and in a great spot - In an interview on CNBC's Mad Money, Ernie Garcia said "We're going to keep getting gains and look to grow again soon." About 18 months ago, Carvana turned its focus on profitability, he noted. It has cut SG&A significantly over that period. Currently, the company is testing same day delivery in a few markets. He expects car prices to come down over time.

18:18 EST Senti Bio enters strategic development with Celest Therapeutics - Senti Bio announced a new strategic collaboration with Celest Therapeutics, a China-based biotechnology company, for the clinical development of SENTI-301A to treat solid tumors in China. Through this collaboration, Celest will lead clinical development, operations, and manufacturing for the advancement of SENTI-301A with technical support from Senti Bio. Celest plans to enroll patients initially through a pilot trial in mainland China and expects to enroll the first patient in the first half of 2024. Celest and Senti Bio have the option to expand clinical development of SENTI-301A to Hong Kong, Macau and Taiwan. Senti Bio will retain all commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan for SENTI-301A. Under the terms of the collaboration, Senti Bio will be eligible to receive up to $156M in certain milestone payments, in addition to potential tiered royalty payments. Other terms of the transaction were not disclosed. The planned dose finding trial will include nine patients with advanced glypican 3-expressing hepatocellular carcinoma across two dose cohorts. Endpoints will include safety assessments for adverse events and dose limiting toxicities, as well as efficacy analyses using standard response criteria for liver cancer.

17:49 EST Air Transport Services names Joe Hete CEO - Air Transport Services Group announced that its Board of Directors has appointed Joe Hete, current Chairman of the Board and the company's former longtime Chief Executive Officer, as ATSG's CEO, effective immediately. Hete succeeds Rich Corrado, who is leaving his role as CEO of the company, effective immediately. Hete will continue as Chairman of the Board. Randy Rademacher, Lead Independent Director, said, "After careful consideration by the Board, we determined that Joe is the right leader to accelerate our strategy and capitalize on the long-term opportunities ahead. As Chairman for the past three years and having previously served as CEO of ATSG for 17 years, Joe has extensive knowledge of our business and its competitive position within the industry. He is uniquely qualified to step into this role to optimize our current performance and position ATSG for the future. Under Joe's leadership, we believe the Company will be well-positioned to continue building on its strong foundation, solidifying its market-leading position, and working to deliver meaningful value for our shareholders."

17:35 EST Gatos Silver reports Q3 silver production of 2.2M oz, down 19% from last year - The company states: "Gatos Silver is increasing its full year 2023 guidance for silver production and silver equivalent production as a result of good operational performance in the first month of the fourth quarter and recent optimization of the mine plan. Silver production is now expected to be between 8.8 and 9.3 million ounces compared with original guidance of 7.4 to 8.2 million ounces. This represents an increase of 19% at the low end of the range and 13% at the high end. Silver equivalent production is now expected to be between 13.8 and 14.6 million ounces, compared with original guidance of 12.4 to 13.8 million silver equivalent ounces. This represents an increase of 11% at the low end of the range and 6% at the high end. Based on the revised mine plan sequencing at CLG, the Company expects full year zinc and gold production to be near the low end of the original guidance range of 57 to 63 million pounds and 5.4 to 6.2 thousand ounces respectively. Full year lead production is expected to be within the upper half of the original guidance range of 36 to 40 million pounds."

17:25 EST Volaris reports capacity increased 2.4% in October - The company said, "In October 2023, Volaris' capacity (measured in ASMs) increased by 2.4% year-over-year, while demand (measured in RPMs) increased by 2.2%; the result was a load factor decrease of 0.2 pp YoY to 89.5%. Volaris transported 2.7 million passengers during the month, a 2.4% decrease compared to October 2022. Demand (measured in RPMs) in the Mexican domestic market decreased by 5.2%, while demand increased by 20.1% in the international market."

17:14 EST Google's You Tube testing new experimental generative AI features - A You Tube blog posting, said in part: "In addition to the AI tools we recently shared that help make it easier to create on YouTube, we're testing two experiments that integrate generative AI into the YouTube viewing experience. Because these experiments are very small, you might not see them just yet! If you are a Premium member, you may be eligible to test these experiments at youtube.com/new. If you do try these experiments, let us know what you think by sending feedback. Here's more about the experiments: To help you easily understand and participate in comment conversations, we're experimenting with AI that organizes large comment sections of long-form videos into easily digestible themes. If you're part of this experiment, when you open the comment section on mobile, you'll see a new option to sort by Topics on some videos. Creators can use these comment summaries to more quickly jump into comment discussions on their videos, or to draw inspiration for new content based on what their audiences are discussing. If creators want to remove any comment topics, they can delete individual comments that show up under the specific topic. Also, topics are pulled from published comments only and cannot be created from comments that are held for review, contain blocked words or are from blocked users. This experiment is running on a small number of videos in English that have large comment sections. YouTube Premium members, starting later today, you can opt-in to test this out at youtube.com/new. Keep in mind anyone testing this feature out won't see it on every YouTube video." Reference Link

17:06 EST Gilead and Arcus Biosciences report results from EDGE-Gastric study - Gilead Sciences (GILD) and Arcus Biosciences (RCUS) announced that domvanalimab plus zimberelimab and chemotherapy showed encouraging overall response rate and six-month progression-free survival, or PFS, rate results in a preliminary analysis from Arm A1 of the EDGE-Gastric study. This ongoing Phase 2, multi-arm, global study is evaluating the safety and efficacy of various combinations of the Fc-silent anti-TIGIT antibody domvanalimab plus the anti-PD-1 antibody zimberelimab and chemotherapy in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma. These results will be presented tomorrow during the American Society of Clinical Oncology, or ASCO, Monthly Plenary Series, a virtual forum for presentation and discussion of the latest cancer research. At data cutoff, September 4, 2023, 41 patients were enrolled and treated with a median follow-up of 8.1 months; 24 patients, or 59%, remained on study treatment at time of data cutoff. Median time on treatment was 33 weeks. The domvanalimab-containing regimen showed an objective response rate (ORR) of 80% in patients with PD-L1-high tumors, 46% in patients with PD-L1-low tumors (TAP less than5%) and 59% for patients overall. There were two confirmed complete responses. Six-month landmark PFS rate was 93% for patients with PD-L1-high tumors, 68% for patients with PD-L1-low tumors and 77% for patients overall. Median PFS was not reached and mature PFS data are expected in the second half of next year.

17:00 EST TripAdvisor jumps 11% to $17.95 after Q3 results beat estimates

16:53 EST Brookdale Senior Living sees FY23 non-development CapEx $195M - The company said, "In the aggregate, the Company expects its FY23 non-development capital expenditures, net of anticipated lessor reimbursements, to be approximately $195.0M, excluding reimbursable remediation costs at the Company's communities resulting from 2022 natural disasters. The Company anticipates an additional approximately $28.0M in reimbursable remediation costs at the Company's communities resulting from 2022 natural disasters, and such costs are expected to be reimbursed from the Company's property and casualty insurance policies in 2023 or 2024."

16:48 EST NextEra to sell Texas natural gas pipeline portfolio for $1.815B to Kinder - NextEra Energy Partners (NEP) announced that it has entered into a definitive agreement with Kinder Morgan (KMI) to sell its Texas natural gas pipeline portfolio for $1.815B. Under the agreement with Kinder Morgan, NextEra Energy Partners plans to sell its Texas natural gas pipeline portfolio for a purchase price of $1.815B. The closing of the sale, which is planned to occur in the first half of 2024, is subject to receipt of Hart-Scott-Rodino anti-trust approval, the effectiveness of certain contract amendments and customary closing conditions. The Texas natural gas pipeline portfolio is primarily comprised of seven pipelines which provide natural gas to Mexico and power producers and municipalities in South Texas. The total 2023 calendar-year adjusted EBITDA for the Texas natural gas pipeline portfolio is expected to be approximately $181M, with roughly 70% associated with the transmission portion of the portfolio and the remaining 30% associated with the midstream pipelines. The sale price represents an approximate 10 times multiple on the estimated calendar-year 2023 adjusted EBITDA. Upon closing of the Texas natural gas pipeline portfolio sale, NextEra Energy Partners intends to use the net proceeds from the sale to: Pay off the outstanding Texas pipeline portfolio's project-related debt and associated interest rate swaps of approximately $425M; complete the $1.1B buyout remaining under the NEP Renewables II CEPF by June 2025; and use the remaining proceeds to pay down a portion of the outstanding corporate revolver. From a base of its Q2 distribution per common unit at an annualized rate of $3.42, NextEra Energy Partners continues to see 5%- 8% growth per year in limited partner distributions per unit, with a current target of 6% growth per year, as being a reasonable range of expectations through at least 2026. For FY23, the partnership expects the annualized rate of the Q4 distribution that is payable in February of 2024 to be $3.52 per common unit. Assuming successful closing of the pipeline transaction, the partnership does not expect to require growth equity until 2027. The partnership expects its payout ratio to be in the mid-90s through 2026. NextEra Energy Partners does not expect to need an acquisition in 2024 to meet the 6% growth in distribution per unit target.

16:43 EST Kinder Morgan to buy NextEra Energy Partner's STX Midstream for $1.8B - Kinder Morgan "announced that it has agreed to acquire NextEra Energy Partner's South Texas assets, STX Midstream, for $1.815 billion. The STX Midstream pipeline system includes a set of integrated, large diameter high pressure natural gas pipelines that connect the Eagle Ford basin to key growing Mexico and Gulf Coast demand markets. STX Midstream includes a 90% interest in the NET Mexico pipeline; MGI Enterprises, a PEMEX affiliate, owns the other 10%. STX Midstream owns and operates Eagle Ford Midstream, a 158-mile residue line connecting the Eagle Ford basin to the Agua Dulce Hub in Nueces County, Texas. Eagle Ford Midstream is connected to multiple pipeline systems, including KMI's Tennessee Gas Pipeline, Kinder Morgan Tejas Pipeline and Natural Gas Pipeline Company of America. STX Midstream also owns a 50% interest in Dos Caminos LLC, which is operated by, and the other 50% interest owned by, Howard Energy Partners. Dos Caminos has placed in service a 62-mile pipeline that connects HEP's existing midstream pipeline and facilities in Webb County, Texas to KMI's new Eagle Ford pipeline, which was recently placed in service. The portfolio of assets is highly contracted, with an average contract length over 8 years. Approximately 75% of the business is supported by take-or-pay contracts."

16:37 EST Asur reports October total passenger traffic down 0.4% y/y - Asur announced that passenger traffic for October 2023 reached a total of 5.4M passengers, representing a decrease of 0.4% compared to October 2022. Passenger traffic increased year-on-year by 4.1% in Mexico and 16.8% in Puerto Rico 16.8%, while traffic in Colombia declined 18.8%. Passenger traffic growth in Mexico and Puerto Rico was mainly driven by domestic traffic of 8.6% and 14.5%, respectively, while international traffic increased 40.0% in Puerto Rico and declined 1.2% in Mexico. Passenger traffic in Colombia was negatively affected by the suspension of operations of two local airlines since the beginning of 2023.

16:34 EST Investors Title Company declares $4.00 per share special dividend - Investors Title Company announced that the Company's Board of Directors declared a special cash dividend of $4.00 per share to shareholders of record on December 1, 2023, payable December 15, 2023.

16:30 EST Ventyx Biosciences trading resumes

16:20 EST Celanese names Scott Richardson COO, Chuck Kyrish CFO - Celanese Corporation announced a series of new leadership appointments across its Executive Leadership Team. Scott Richardson has been named Executive Vice President and Chief Operating Officer (COO), effective November 8, 2023, with responsibility for Engineered Materials, the Acetyl Chain, manufacturing, supply chain, and procurement. Chuck Kyrish will join the ELT and has been named Senior Vice President and Chief Financial Officer, effective November 8, 2023. Chuck is currently serving as Vice President of Corporate Finance with responsibility for accounting, treasury, internal audit, and tax. Anne (Lynne) Puckett will step down from her role Senior Vice President and General Counsel and will serve in a transition role through early 2024 after which she will depart after 5 years with Celanese. All other members of the Celanese ELT will maintain their current roles. In addition to supporting Scott in enhancing the earnings growth of the businesses, Lori Ryerkerk, Chairman and Chief Executive Officer, will have direct leadership for strategy, M&A, finance, legal, HR, and IT.

16:14 EST Fuel Tech awarded air pollution control orders totaling $2.6M - Fuel Tech "announced the receipt of multiple air pollution control contracts from new and existing customers in the US and South Africa. These awards support projects serving various end markets and have an aggregate value of approximately $2.6 million. An order was received from an existing customer in the US for two ULTRA(R) systems to be installed on natural gas-fired package boilers at a university in the Southwest. Fuel Tech's ULTRA process provides for the safe and cost-effective on-site conversion of urea to ammonia for use as a reagent where Selective Catalytic Reduction (SCR) is used to reduce NOx, eliminating the hazards associated with the transport, storage and handling of anhydrous or aqueous ammonia. A second ULTRA contract from this same customer is for a gas-fired package boiler which can be used at multiple customer locations. Respective deliveries are due to be completed in the first and second quarters of 2024."

16:12 EST Lucid Group to adopt North American Charging Standard in 2025 - Lucid Group (LCID) announced that all Lucid vehicles built with the current Combined Charging System will be able to charge at stations in the Tesla (TSLA) Supercharger network by using an adapter in 2025. In addition, Lucid will integrate the North American Charging Standard into future vehicles in 2025. "Adopting NACS is an important next step to providing our customers with expanded access to reliable and convenient charging solutions for their Lucid vehicles," said Peter Rawlinson, CEO and CTO at Lucid. "We believe that a unified charging standard, backed by the nationwide rollout of future-ready higher-voltage charging stations, will be a critical step in empowering American consumers to adopt electric vehicles."

16:10 EST Compass sees FY23 Non-GAAP Operating expense $850M-$950M

16:09 EST Metropolitan Bank names Daniel Dougherty CFO - Metropolitan Bank Holding Corp. announced the promotion of Daniel F. Dougherty, CFA, to Executive Vice President and Chief Financial Officer, effective November 6, 2023. Mr. Dougherty assumes this role following the resignation of Greg Sigrist on October 31, 2023. He will report directly to Mark R. DeFazio, President and Chief Executive Officer. In his new capacity, Mr. Dougherty will oversee treasury, investor relations, tax, capital planning, accounting, and financial reporting. Mr. Dougherty joined Metropolitan Commercial Bank in July 2022 as First Vice President and Treasurer, bringing a distinguished 25-year banking career with significant roles at local and national banks. His prior positions include Executive Vice President and Treasurer at Investors Bank, Senior Vice President and Treasurer at Astoria Bank, Senior Vice President and Assistant Treasurer at Israel Discount Bank of New York, and Portfolio Manager positions at North Fork Bancorporation and GreenPoint Financial Corp.

16:07 EST Howard Hughes sees FY23 MPC EBT up 10%-20% from last year - FY23 MPC EBT, which was revised in the prior quarter to be flat to down 10% year-over-year, has continued to benefit from increased sales of new homes in Bridgeland, Summerlin, and The Woodlands Hills year-to-date. With low inventories of new homes and vacant lots, homebuilder interest in new acreage continues to strengthen, and the Company expects material land sales during the fourth quarter. As a result, 2023 MPC EBT is now expected to be up 10% to 20% year-over-year, with a mid-point of approximately $325 million. This represents a $125M improvement at the mid-point compared to the initial full-year guidance issued in early 2023. Operating Assets NOI, previously projected up 1%-4% year-over-year, has benefited from strong multi-family rent growth and lease-up at new developments in Bridgeland, Downtown Columbia, and Summerlin which encompass nearly 1,400 units. The office portfolio has also delivered solid financial performance year-to-date, benefiting from expiring abatements; however, strong leasing momentum in recent quarters is not expected to have a material impact on 2023 results due to free-rent periods on many of the new leases. Overall, excluding the $3.4M contribution from divested retail assets in the prior year, Operating Assets NOI is now expected to be in a range of up 2% to 4% year-over-year, with a mid-point of approximately $243M. This represents a $7M improvement at the mid-point compared to the initial full-year guidance issued in early 2023. Condo sales revenues, which were previously projected to range $40M-$45M with gross margins between 10%-13%, are now expected to be $47M-$48M with gross margins of 13% to 14%. 2023 condo sales revenues and gross margins are entirely driven by the closing of remaining units at 'A'ali'i and Kundefined'ula, which were 100% and 99.8% sold, respectively, as of September 30. The final unit at Kundefined'ula closed in the fourth quarter. Despite lower margins on these remaining units in the current year, overall gross margins for 'A'ali'i and Kundefined'ula remained in a range of 25%-30%. The next major condo project scheduled to be completed is Victoria Place, which is expected to be delivered in 2024 and is 100% pre-sold. Cash G&A guidance is unchanged and is projected to range between $80M-$85M, which excludes anticipated non-cash stock compensation of approximately $5M.

16:01 EST Novo Nordisk initiates new share repurchase program of up to DKK 4.1B - The execution of Novo Nordisk A/S' overall share repurchase program for 2023 of DKK 30B continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase program of up to DKK 4.1B in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council, the company stated. The purpose of the program is to reduce the company's share capital and to meet obligations arising from share-based incentive programs. B shares of DKK 0.10 will be repurchased during the trading period starting November 7, 2023 and ending on January 29, 2024. A maximum of 350,000,000 B shares of DKK 0.10 in total can be bought during the trading period.

16:00 EST Ventyx Biosciences trading halted, news pending

15:03 EST Aura Biosciences reports agreement from FDA under SPA for CoMpass trial - Aura Biosciences announced it has received agreement from the U.S. Food and Drug Administration under a Special Protocol Assessment, or SPA, for the design and planned analysis of CoMpass, the company's global Phase 3 clinical trial of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma, or CM. The company also announced the presentation of positive Phase 2 safety and efficacy data of bel-sar with 90% of patients at twelve months of follow-up evaluating two key clinical endpoints: tumor control and visual acuity preservation using suprachoroidal route of administration for the first-line treatment of adult patients with early-stage CM. The results were presented at the American Academy of Ophthalmology, or AAO, 2023 Annual Meeting in San Francisco, California. "This written agreement from the FDA is consistent with our regulatory strategy and reaffirms that the design and planned analysis of the CoMpass Phase 3 clinical trial, if successful, adequately address the objectives necessary to support a biologics license application submission for bel-sar for the treatment of early-stage CM. We are excited with the momentum in the ocular oncology community to participate in what would be the first ever registration-enabling clinical trial for early-stage CM," said Dr. Jill Hopkins, Chief Medical Officer and President of R&D of Aura Biosciences. Aura added: "The company received written agreement from the FDA under an SPA for the design and planned analysis of the Global Phase 3 CoMpass trial indicating concurrence by the FDA with the adequacy of the study, if successful, to address the objectives necessary to support the company's planned biologics license application submission. The Phase 3 trial is designed as a superiority trial comparing bel-sar versus sham. The trial is a global, multi-center, masked study, and it is intended to enroll approximately 100 patients randomized 2:1:2 to receive high dose regimen of bel-sar with SC administration, low dose regimen of bel-sar with SC administration, or a sham control. The primary endpoint is time to tumor progression, and the first key secondary endpoint is a composite time to event analysis that will compare the tumor control and visual acuity of the bel-sar high dose regimen to sham when the last patient completes their 15 months of follow up. The trial is powered at greater than 90%. The company is on track to dose the first patient in Q4 2023."

13:43 EST A.O. Smith targets adjusted EPS CAGR of 7%-9% in 2024-2028 - A.O. Smith targets adjusted EPS compound annual growth rate, or CAGR, of 7%-9% in 2024-2028 and targets annual revenue growth of 5%-6% over that timeframe. Guidance from slide presentation for the 2023 Investor Day scheduled on November 6. Reference Link

12:00 EST Tecnoglass falls -10.7% - Tecnoglass is down -10.7%, or -$3.67 to $30.59.

12:00 EST V2X falls -12.9% - V2X is down -12.9%, or -$6.66 to $44.78.

12:00 EST Posco rises 15.9% - Posco is up 15.9%, or $13.23 to $96.67.

11:46 EST Novo Integrated Sciences announces 1-for-10 reverse stock split - Novo Integrated Sciences announced that the Company will undertake a reverse stock split of its common stock at a ratio of 1-for-10. The Reverse Stock Split is expected to become effective immediately after the close of trading on the Nasdaq Capital Market on November 6, 2023 and the Company's common stock is expected to begin trading on Nasdaq on a Reverse Stock Split-adjusted basis on November 7, 2023, under the new CUSIP number, 67011T300.

11:40 EST Quad-C closes sale of investment in MNX to UPS - Quad-C Management has closed the sale of its investment in MNX Global Logistics to UPS. MNX specializes in time-critical life sciences, medical device and healthcare shipments, as well as mission-critical parts for grounded aircraft and just-in-time industrial and automotive supply chains, and has a network of forward stocking locations to ensure rapid delivery of customer inventory.

11:08 EST AAON appoints Matt Tobloski as president, COO - AAON announced that its Board of Directors has appointed Matt Tobolski to the role of AAON President and COO. Gary Fields, the Company's President, CEO and Director, will continue to serve as CEO and a member of the Board of Directors. Matt joined AAON in December 2021 following the acquisition of BASX, where he currently serves as President and Co-Founder. In this new role, Matt will lead AAON's operations, engineering, sales, marketing, and administration teams overseeing approximately 3,800 employees across the organization. He will continue to build upon AAON's decades of innovation, manufacturing prowess and customer-focused mindset while leveraging the talents and manufacturing capacity that exist across the entire AAON organization. Additional alignment of the executive leadership team will occur to leverage resources and organizational efficiencies with globally focused roles and collaborative site leadership. Dave Benson is appointed AAON Vice President and President of BASX, where he currently serves as Co-Founder and Chairman. Dave will take over Matt's responsibilities at BASX and provide site leadership in Redmond, Oregon. Stephen Wakefield will assume the role of AAON Vice President and Executive Vice President of AAON Oklahoma continuing with many of the same job responsibilities and providing site leadership for the Oklahoma and Missouri locations. Doug Wichman will continue in his role as AAON Vice President and President of AAON Coil Products providing site leadership for the Texas facility. Alignment and addition of globally focused roles will occur to leverage the skills and talents across the organization and continue to drive our One AAON culture. Rob Teis is changing roles to Vice President of Business Technology to provide critical leadership as AAON continues evolving systems and processes across the organization. Previously, Rob was Vice President of Sales and Marketing. Andrew Edmondson will be promoted to AAON Executive Director of Sales and Marketing, taking over most of Rob's prior duties. Larry Honel will be promoted to Executive Director of Global Operations and Whitney Wakefield will be promoted to Executive Director of Production Controls. All changes in this announcement are effective January 1, 2024.

10:13 EST Freeline Therapeutics Holdings PLC (ADR) trading resumes

10:03 EST Freeline Therapeutics Holdings PLC (ADR) trading halted, volatility trading pause

10:00 EST Gol Linhas falls -12.2% - Gol Linhas is down -12.2%, or -43c to $3.13.

10:00 EST Westwood Holdings Group rises 10.4% - Westwood Holdings Group is up 10.4%, or $1.13 to $12.04.

10:00 EST Bluegreen Vacations rises 105.7% - Bluegreen Vacations is up 105.7%, or $37.55 to $73.07.

09:47 EST Sunlands Online falls -13.6% - Sunlands Online is down -13.6%, or -81c to $5.16.

09:47 EST Trinseo rises 12.4% - Trinseo is up 12.4%, or 82c to $7.45.

09:47 EST Bluegreen Vacations rises 105.5% - Bluegreen Vacations is up 105.5%, or $37.48 to $73.00.

09:38 EST reAlpha Tech Corp trading resumes

09:33 EST Liang Meng, Ascendent Capital propose $26 per share offer to acquire Hollysys - On November 6, Liang Meng, Ascendent Capital and Advanced Technology submitted a letter to the special committee of the board of directors of Hollysys and expressed their intention to actively pursue an acquisition of the company. The group have proposed a non-binding, all-cash offer of $26 per share, which values the company at approximately $1.61B. "The reporting persons may also acquire additional ordinary shares through open market purchases and private agreements. The reporting persons support the efforts by other shareholders to cause a special meeting of the shareholders to be held. The reporting persons request that the special meeting be held no later than December 1, 2023," according to a regulatory filing. Reference Link

09:31 EST Crown Electrokinetics executes master services agreement with Arizona customer - Crown Electrokinetics announced it has executed a Master Services Agreement for micro-trenching with its second customer in Arizona, one of the largest fiber optics companies in the United States. The company offers a high-speed broadband internet service that uses fiber optic cable, and wireless millimeter wave technology on select multi-family buildings, to deliver fast internet right to homes or businesses. Crown expects to commence the project later this month through the deployment of additional newly acquired micro trenching equipment.

09:24 EST NRG Energy announces $950M accelerated share repurchase program - NRG Energy announced that it has entered into accelerated share repurchase, or ASR, agreements with multiple dealers to repurchase $950M of NRG's common stock. Under the ASR agreements, NRG will pay $950M to the dealers and receive shares of NRG's common stock from each dealer on the specified settlement dates. NRG expects to receive over 80% of the shares to be repurchased during the initial settlement period. The total number of shares purchased by NRG pursuant to the ASR agreements will generally be based on the volume-weighted average prices of NRG's common stock during the term of each ASR agreement, less a discount. The final settlement of the transactions is expected to occur in the first quarter of 2024.

09:18 EST Cassava Sciences completes patient enrollment for Phase 3 program of simufilam - Cassava Sciences announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in Alzheimer's disease dementia. Simufilam is Cassava Sciences' proprietary oral drug candidate. This investigational drug binds to altered filamin A protein in the brain and restores its normal shape and function. By targeting altered filamin A, simufilam may help patients with Alzheimer's achieve better health outcomes. A total of 1,929 patients were randomized in two on-going Phase 3 trials of simufilam. These are registrational studies, meaning if positive data and results are generated, they can support the filing of a new drug application for simufilam in Alzheimer's disease. Both Phase 3 studies received a Special Protocol Assessment from the FDA. The first Phase 3 trial has a 52-week treatment period; 804 Alzheimer's patients were randomized into this study, as announced in October 2023. Top-line results for the 52-week Phase 3 study are currently expected approximately year-end 2024. The second Phase 3 trial has a 76-week treatment period; 1,125 Alzheimer's patients were randomized into this study. Top-line results for the 76-week Phase 3 study are currently expected approximately mid-year 2025. Patients with mild-to-moderate Alzheimer's disease dementia who met study eligibility criteria were recruited into the Phase 3 program from clinical sites in the U.S., Puerto Rico, Canada, Australia and South Korea. Cassava Sciences is conducting its on-going Phase 3 program in collaboration with Premier Research International, a global contract research organization/

09:09 EST ADW Capital calls on GFL Environmental to undertake strategic review - ADW Capital Management issued an open letter to GFL's board of directors and management team regarding opportunities to maximize value for all shareholders and urging the Company to undertake a strategic review process. The letter read, in part, "ADW Capital Management are significant and long-term shareholders of GFL Environmental, currently owning 1,650,000 of the Company's shares. We begin this letter with the following quote: "The definition of insanity is doing the same thing over and over again and expecting a different result." ADW Capital has been a shareholder of the Company since shortly after its initial public offering and in many ways, today GFL is an entirely different Company and yet its valuation and discount to peers is EXACTLY the same or WORSE. We believe GFL is an extremely valuable company that the public markets are unable to appreciate today and perhaps never will be able to. GFL is simply too cheap a stock on an absolute basis given the quality and durability of its future growth especially in this uncertain economic / inflationary environment. The multiple differential relative to its competitors is even more perplexing given its faster growth profile and prospects for future margin expansion. We think your experiment with the public markets should end and the Board should immediately seek to maximize value for shareholders through either selling or merging the company or disposing of assets bringing down leverage materially... Investors appear to be ignoring the facts here and only seeing what they want to see. We believe GFL's "stock story" has turned into an edition of the National Enquirer or People Magazine. Soon after the Company's IPO, it was the target of a long short-selling report that effectively accused GFL's founder and chief executive officer, Patrick Dovigi, of being Italian and in the mob and being a profligate spender because he owned a yacht. To be fair, we understand that Patrick grew up in a small town in Canada playing competitive hockey and bootstrapped this entire business from one single asset. Mr. Dovigi has partnered with multiple private equity firms, sovereign wealth funds, and pension funds since the Company was founded in 2007 - each of whom has earned multiples on their investment according to our research. We believe traditional public market waste investors have a hard time investing in the Company as they are both slaves to beating their public market indices and leery of investing in GFL knowing its largest investors are private equity investors who may have an alternative agenda or investment objectives. Given that background, we believe short-sellers and fear mongers see GFL's public stock as susceptible to hit and run attacks and therefore continue to spread false stories and narratives around about the Company's leverage profile and character assassinations of the Company's CEO to take advantage of the spineless nature of traditional long only waste investors. GFL continues to operate in an ivory tower, thinking it can just tell the market what the Company is worth and the market will believe them. Frankly, we believe the Company should return to the private markets. It is clear to us that GFL is in a unique position based on its portable capital structure and is a generational/inflation-proof asset for a large-scale private equity firm or a "collector of trophies", such as a sovereign wealth fund, holding company, or similarly situated investor. On the same note, we believe one of the larger waste management companies could execute a stock for stock merger with the Company and get the best operating team in the space and realize material synergies. Absent the aforementioned options, in our view, the only other strategy would be to divest a large portfolio of assets where the Company is not as active in tuck-in M&A or the returns are not as good as other investments the Company sees in front of it - renewable natural gas, tuck-in, et. al. When the Company announced its first round of major asset divestitures the prospective de-leveraging was initially very well received by the market, and then later shares immediately deflated after the Company announced additional internal investments in environmental initiatives/RNG at multiples far lower than any other capital that could be deployed in their portfolio.10 This Company is the definition of guilty-until-proven-innocent and the broader investing public just "does not want to believe." We believe the interests of the private equity firm that exercises significant influence on the Company's board of directors are misaligned with the rest of the shareholder base because the investment sits in a fund that is in the money based on our research and all they would be doing is handing back future earnings / carry by relinquishing / selling the investment today. We are sure it is not lost on anyone that private equity firms are having a challenging time raising capital for new funds. So, why not just hang on to old investors' capital as a call option on free money? The Board and management have a fiduciary obligation to maximize value for ALL shareholders and we encourage them to immediately engage a financial advisor to pursue a review of strategic alternatives. ADW Capital has a longstanding history of working constructively with boards of directors and management teams to unlock value in "orphan" companies in the public market and would appreciate the opportunity to present to the Board and management."

09:08 EST PLBY Group completes sale of TLA Acquisition, Lovers retail business - PLBY Group announced the completion of its sale of TLA Acquisition Corp. and its Lovers retail business. The sale of 100% of the equity of Lovers to LV Holding, LLC, an affiliate of Flynt Management Group, LLC, was completed for cash consideration to PLBY Group of $13.5 million, subject to certain adjustments. The Company previously announced the signing of a definitive agreement for the transaction on October 3, 2023.

09:07 EST Sermonix announces case report during ELAINE-1 study of Lasofoxifene - Sermonix Pharmaceuticals announced that a case report detailing a durable complete remission during its Phase 2 ELAINE-1 study was published in JCO Precision Oncology. The case marks the first-ever known finding of a complete clinical remission in a metastatic estrogen receptor-positive/HER2- breast cancer patient with an ESR1 mutation after prior CDK4/6 inhibitor treatment upon participation in any single-agent hormonally based therapy trial. The open-access case report, "Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation," details a patient result that was reported during Sermonix's Evaluation of Lasofoxifene in ESR1 Mutations study. Sermonix licensed Lasofoxifene globally from Ligand Pharmaceuticals. The case was previously presented as a poster and brief talk at the annual Metastatic Breast Cancer Research Conference in September 2022. Topline results from the ELAINE-1 trial, including this patient, were reported at the European Society for Medical Oncology, ESMO, Congress 2022. "To witness a study participant with advanced breast cancer achieve a durable complete remission for more than two years while taking lasofoxifene is a reminder to everyone at Sermonix why we do what we do; it drives our daily and long-term vision for this drug," said Dr. David Portman, Sermonix founder and chief executive officer. "We are excited the details of this complete responder - the only one to our knowledge achieved in the post-CDK4/6i-ESR1 mutation setting with single-agent endocrine therapy - will be shared with a broader audience through JCO Precision Oncology and we look forward to lasofoxifene's continued clinical development during our current Phase 3 ELAINE-3 registrational study."

09:05 EST Chemed announces additional $300M for stock repurchase - Chemed announced that the Board of Directors has formally authorized an additional $300M for stock repurchase under Chemed's existing share repurchase program. These share repurchases will be funded through a combination of cash generated from operations as well as utilization of its revolving credit facility. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services.

09:05 EST Palo Alto Networks intends to acquire browser start-up Talon Cyber Security - Palo Alto Networks has entered into a definitive agreement to acquire Talon Cyber Security, a pioneer of Enterprise Browser technology. Talon's Enterprise Browser provides a solution that, when combined with Prisma SASE, aims to enable users to securely access business applications from any device, including mobile and other non-corporate devices.

09:04 EST Veeco ships first nanosecond annealing system to Tier 1 customer - Veeco Instruments shipped its first NSA500 Nanosecond Annealing System to a Tier 1 logic customer. With this product launch, Veeco solidifies its leadership in advanced laser annealing technology. The NSA500 is targeted at low thermal budget and material modification applications which are of increasing importance for advanced node and 3D applications. Compared to traditional annealing solutions, the NSA500 System is able to precisely anneal relevant surface layers without damaging the underlying device due to its nanosecond scale dwell time and high temperatures. Veeco is planning shipment of its second evaluation system to another Tier 1 customer within the next few months and sees potential for initial high-volume manufacturing orders in late 2024 or 2025. The broad applicability of Veeco's NSA500 system provides a significant opportunity to expand the company's served available market to new applications. These include low thermal budget applications like Backside Power Delivery and Contact Annealing for advanced nodes and material modification applications such as void-removal, recrystallization and grain growth.

09:03 EST LPL Financial: GER Loftin joins broker-dealer, RIA, custodial platforms - LPL Financial announced that GER Loftin Wealth Advisors has joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported having served approximately $225 million in advisory, brokerage and retirement plan assets, and join LPL from United Planners Financial Services.

09:01 EST Digital Brands announces review of strategic alternatives - Digital Brands has unanimously decided to initiate a formal review to explore strategic alternatives for the company. The comprehensive review will begin immediately and will evaluate a broad range of options to maximize shareholder value. Digital Brands Group has not set a deadline or definitive timetable for the completion of this process, and there can be no assurance that this process will result in any particular outcome.

08:54 EST Jabil acquires Retronix, terms undisclosed - Jabil announced the successful acquisition of Retronix, a provider in the reclamation and refurbishment of electronic components, completed earlier this year. The deal adds exclusive technologies to Jabil's portfolio. These services enable the safe extraction of embedded valuable components from printed circuit boards, or PCBs, and other electronics to minimize waste, create new value channels, and mitigate future component obsolescence. The deal adds to Jabil's current circular economy services including reverse supply chain management, medical device reprocessing, recycled packaging, and emission reductions. It strengthens Jabil's mission to offer sustainable options to its customers who are increasing the use of electronics in "smart" products like electronic vehicles, home appliances, medical devices, and even packaged goods.

08:49 EST Ondas' Airobotics awarded $2.6M order for Optimus drone systems - Ondas Holdings has received a $2.6M order for immediate delivery of additional Optimus Systems from a local governmental entity in Dubai for public safety and emergency response operations. Since 2020, the Optimus System has been extensively utilized by this local governmental entity in Dubai which has carried out thousands of operational drone flights without human intervention under challenging environmental conditions in densely populated areas demonstrating urban drone infrastructure for Public Safety and Emergency Response use cases.

08:48 EST Conduent announces implementation of online portal for Mississippi - Conduent announced the implementation of an online portal for Mississippi's Division of Medicaid and Department of Human Services. The solution offers state residents improved access to apply for and manage their benefits. Mississippi residents can now use Conduent's BenePath Self-Service Portal to enroll in and manage a range of state benefits, such as Medicaid, Children's Health Insurance Program, Supplemental Nutrition Assistance Program, Temporary Assistance for Needy Families and Low-Income Home Energy Assistance Program. "We're proud to support Mississippi and its beneficiaries with our BenePath solution to advance self-service for eligibility and benefits management," said Mark King, President, Conduent Government Solutions. "We appreciate the trust that the agencies have placed in Conduent, and we look forward to helping the state enable seamless constituent interactions."

08:46 EST Adeia appoints Turner-Brim to board of directors - Adeia announced that veteran intellectual property attorney and advisor, Phyllis Turner-Brim, joined Adeia's board of directors on Friday, November 3, 2023. Turner-Brim brings to Adeia a three-decade IP legal career with 15 years of executive experience advising C-suite executives and senior leaders -- including those in Fortune 500 companies -- on issues ranging from strategy and marketing to technology management and IP enforcement.

08:46 EST Ainos signs MOU for contract clinical trials with SIDSCO Medical - Ainos signed a Memorandum of Understanding with SIDSCO Biomedical. The MoU is an important step in Ainos' strategy to expand its product line into the global pet care market. Under the agreement, Ainos and SIDSCO will jointly explore the feasibility of VELDONA/Cytoprotein contract clinical trials. Ainos intends to conduct animal clinical trials for veterinary investigational medicines in conjunction with SIDSCO, and will provide the technical knowledge, funding, and assistance required for the project. Ainos' upcoming clinical trial is expected to be sent to the United States' Internal Animal Care and Use Committee for review in December this year. The clinical trial is a small-scale field pre-trial. It is expected to start accepting cases in the first quarter of next year, and to complete admission of 15-30 cats in the second quarter. If the results of this trial meet the expected efficacy requirements, the Company will submit a formal application to Taiwan's Bureau of Prevention and Inspection of the Ministry of Agriculture for animal new drug field trials. This would represent a significant step forward in the process of obtaining an animal new drug license. Ainos plans to conduct the upcoming clinical study in cooperation with SIDSCO at Mercy Animal Medical Center.

08:44 EST Kineta announces new data from VISTA-101 trial of KVA12123 - Kineta announced today the presentation of new positive data from its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, the company's VISTA blocking immunotherapy, in patients with advanced solid tumors at the Society for Immunotherapy of Cancer's, SITC, 38th Annual Meeting. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, presented the company's poster unveiling the new clinical data. The Phase 1/2 VISTA-101 trial enrolled 11 patients with advanced solid tumors in the first three monotherapy dose-escalation cohorts, where subjects received either 3, 10 or 30 mg of KVA12123 by intravenous infusion every two weeks. Primary objectives of the Phase 1/2 study are to evaluate the safety and tolerability of KVA12123 and to determine the recommended Phase 2 dose. Patients enrolled in the study were heavily pretreated with multiple prior lines of therapy including chemotherapy, radiation and immunotherapy. Additional monotherapy and initial combination therapy data are anticipated in the second quarter of 2024. Key highlights from the poster presentation: Safety: eleven patients were dosed and cleared the first three monotherapy cohorts. KVA12123 was well tolerated at all doses and no dose limiting toxicities were observed. All KVA12123 treatment emergent adverse events were grades 1-2. Pharmacokinetics and VISTA Receptor Occupancy: KVA12123 exhibited a greater than dose-proportional pharmacokinetic profile in drug exposure across all evaluated doses, consistent with target-mediated drug disposition at lower doses. biomarkers: KVA12123 demonstrated dose-proportional on-target biomarker immune responses involved in anti-tumor activity. KVA12123 demonstrated significant efficacy-related cytokine induction of CXCL10, MCP1, MIP1alpha and MIP1beta, which are involved in immune cell activation and recruitment to the tumor microenvironment. Additionally, increases in anti-tumor immune cell subpopulations including nonclassical monocytes, NK cells, CD4+ T cells and CD8+ T cells were observed during treatment.

08:42 EST Verb Technology's MARKET.live announces new technology integrations - Verb Technology announces the completion of additional technology integrations, clearing the way to attract and add hundreds of new vendors and brands to its live stream shopping platform. These new improvements now enable seamless integration with the ecommerce solutions powering thousands of vendors' existing ecommerce stores and offers an unprecedented level of inventory management and synchronization, which until now was a limiting factor in the addition of new vendors to the MARKET.live platform.

08:41 EST Align Technology announces $100M open market repurchase - Align Technology announced that it is planning to repurchase $100M of Align's common stock through open market repurchases under Align's $1B stock repurchase program that was approved by Align's Board of Directors in January 2023. This $100 M open market repurchase is in addition to the $250M repurchase of Align's common stock under an accelerated stock repurchase agreement that was announced on October 27. "Invisalign is the most trusted brand in the Orthodontic industry globally and we believe our record Q3'23 teenage shipments reflect market share gains for our clear aligners," said Joe Hogan, president and CEO. "Today's announcement of Align's $100M open market repurchases along with my additional $1M share buyback demonstrates our confidence in our business and commitment to increasing shareholder value. This amount is in addition to the $1.0 million of Align's common stock that Joe Hogan recently purchased in October 2023.

08:40 EST OneMove Capital increases ownership in Dye & Durham - OneMove Capital acquired ownership and control over 300,000 common shares of Dye & Durham Limited on November 2, 2023, pursuant to purchases made through the facilities of the Toronto Stock Exchange at a price of $10.00 per Common Share, for an aggregate purchase price of $3,000,609. Prior to the completion of the Acquisition, OneMove owned and exercised control over 5,215,876 Common Shares. The Common Shares owned and controlled by OneMove immediately prior to the Acquisition represented an aggregate of approximately 9.49% of the then-outstanding Common Shares. Immediately following the completion of the Acquisition, OneMove owns and exercises control over 5,515,876 Common Shares. The Common Shares owned and controlled by OneMove immediately following the Acquisition represent an aggregate of approximately 10.04% of the outstanding Common Shares, resulting in an increased ownership of approximately 0.55% of the outstanding Common Shares. The Acquisition was undertaken by OneMove for investment purposes. OneMove intends to review its investment on a continuing basis. Depending on various factors, OneMove may in the future purchase or sell securities or engage in other activities relating to the Company.

08:38 EST Tabula Rasa HealthCare, ExactCare close business combination - ExactCare announced that the acquisition of Tabula Rasa HealthCare, a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, is complete. ExactCare and Tabula Rasa are creating a leading, independent pharmacy care management company that specializes in caring for the most at-risk patient populations in the healthcare system-helping them to live healthier and thrive in both home- and community-based settings. Together, the two organizations care for over 100,000 beneficiaries served by the Program of All-Inclusive Care for the Elderly, Medicare, Medicaid and Dual-eligible plans.

08:37 EST Southwest Gas adopts tax-free protection plan for Centuri spin-off - Southwest Gas announced actions to help preserve the company's ability to effectuate a tax-free separation of Centuri Group as it considers additional separation alternatives to form a new independent publicly traded utility infrastructure services company. The company remains committed to separating Centuri and continues to assess the value of a potential tax-free spin-off of Centuri, either following, or in lieu of, a potential initial public offering by Centuri as well as other transaction alternatives. Southwest Gas is also considering other taxable transaction alternatives that may use the company's available net operating losses to offset the tax impact in certain cases, including, among other potential structures, a potential sell-down of Centuri shares held by Southwest Gas following an initial public offering of Centuri. The company believes that there is minimal capacity for changes in the ownership of its stock before a 355 Ownership Change could occur. As part of the Plan, the Board declared a dividend of one preferred stock purchase right, which are referred to as "rights," for each outstanding share of Southwest Gas common stock. The dividend will be payable to holders of record as of the close of business on November 17. The rights will initially trade with Southwest Gas' common stock and will generally become exercisable if a person or group, without the approval of the Board, acquires 4.9% or more of Southwest Gas' outstanding common stock. Under the Plan, any person that currently owns 4.9% - or 9.9%, in the case of a passive investor - or more of Southwest Gas' outstanding common stock may continue to own its shares of common stock but may not acquire any additional shares without triggering the Plan. If the rights become exercisable, all holders of rights will be entitled to purchase Southwest Gas common stock at a 50% discount or Southwest Gas may exchange each right held by such holders for one share of Southwest Gas common stock. Rights held by the triggering person will become null and void and will not be exercisable.

08:37 EST IBM, Riyadh Air sign collaboration agreement - Riyadh Air and IBM announced the signing of a strategic agreement in which IBM Consulting will be the lead systems integrator to support creating, building and orchestrating the technology foundation that can help the digitally native airline offer exceptional and seamless travel experiences. Together, Riyadh Air and IBM Consulting have already created the airline's digital and technology strategy. Now, Riyadh Air has selected IBM Consulting to support building the key business and technology capabilities that underpin the strategy. That includes implementing and integrating more than 50 airline industry solutions and core technology capabilities, including security, infrastructure, integration and data platforms, using a hybrid cloud approach. IBM will also orchestrate the work of over 40 partners by providing program and technical governance, project management, quality assurance, change and communications management and training.

08:36 EST OrthoPediatrics enters distribution agreement with Ora Medical - OrthoPediatrics announced the Company has entered into an exclusive Distribution Agreement with Ora Medical, based in Montreal, to sell Ora Medical's gait trainer, The Levity, a device designed for children with walking difficulties. The Levity supports a child with an innovative partial weight bearing mechanism. This allows the child to interact with the world using their arms, unlocking tons of possibilities. Its unique design allows each child to receive a personalized treatment. The Levity comes with versatile features to meet a wide range of needs: body weight support, harness, speed and direction of the device are adjustable, and its foldable design offers ease of transportation. The Levity fits most children between the ages of 3 and 12. Joe Hauser, President of Trauma and Deformity Correction at OrthoPediatrics, added, "Our new partnership with the team at Ora Medical is an exciting step in our non-surgical business. By partnering with great organizations with world-class technology, we can help more children with orthopedic conditions around the world. The Levity gait trainer will be a great addition to our mobility solutions portfolio in the Specialty Bracing brand."

08:35 EST Portage Biotech presents updates on its iNKT, adenosine programs at SITC - Portage Biotech (PRTG) announced the presentations of updates from its ongoing IMPORT-201 Phase 1/2 trial of PORT-2, an invariant natural killer T cell engager for patients with NSCLC and advanced melanoma, and its ADPORT-601 adaptive Phase 1a/1b trial for PORT-6 and PORT-7 in multiple solid tumors at SITC. The patient data from IMPORT-201, a multi-arm Phase 1/2 trial evaluating PORT-2 in multiple settings, included front-line and refractory NSCLC, and refractory melanoma, as a monotherapy and in combination with Merck's (MRK) anti-PD-1 therapy, KEYTRUDA. These data build on previous results shared at the 2023 American Society of Clinical Oncology meeting in June and include new information on the novel pharmacology profile of PORT-2. "We are encouraged by the expanding patient data set that supports results showing PORT-2 having a favorable safety and tolerability profile as a monotherapy as well as early combination data," said Dr. Ian Walters, Chief Executive Officer of Portage Biotech. "We continue to see single agent activity of PORT-2 at the 3 and 9 mg/m2 dose. We are looking forward to exploring higher dose levels as monotherapy and in combination." Dr. Sumit Subudhi from the University of Texas MD Anderson Cancer Center presented the design of the ADPORT-601 trial. This trial will evaluate a potent and selective A2A inhibitor, and an A2B inhibitor, alone and in combination with other immunotherapies specifically in tumors that overexpress adenosine. This trial is being conducted in collaboration with Merck and is being designed to explore A2A + pembrolizumab, A2B + pembrolizumab, and the triplet of A2A + A2B + pembrolizumab.

08:34 EST Aclarion expands immediate Nociscan access with KOL surgeon advisor addition - Aclarion announced that Roger Hartl, M.D., Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, as well as the co-director of New York-Presbyterian Och Spine, will advise the company as a key opinion leader nationally. Over the past 18 months, Aclarion has built a leading consortium of 10 KOL surgeons. Dr. Hartl represents the 10th and final KOL addition to Aclarion's panel. The Company is now in the critical stage of activating MRIs for each of its KOLs so they can begin using the technology, tracking clinical results, and advocating for payer coverage decisions to expand access to Nociscan to all patients. The Company will announce additional MRI activations for the remaining KOLs as they become available and will begin to report on scan volumes as Nociscan use grows with these MRI activations.

08:33 EST Bumble CEO Whitney Wolfe Herd to switch roles, Lidiane Jones to succeed - Bumble (BMBL) announced a leadership succession plan. Lidiane Jones, who currently serves as CEO at Slack, a Salesforce (CRM) company, will succeed Whitney Wolfe Herd as CEO, effective January 2, 2024. Wolfe Herd will transition to the executive chair role at that time.

08:32 EST GigaGen presents IND-enabling data, Phase 1 trial strategy for GIGA-564 - GigaGen presented investigational new drug-enabling data and the clinical trial design for its first-in-human Phase 1 study evaluating the company's oncology candidate, GIGA-564, at the 2023 Society for Immunotherapy of Cancer Annual Meeting. The comprehensive dataset from non-clinical models continues to demonstrate GIGA-564's potential to improve outcomes for cancer patients through weak checkpoint inhibition of CTLA-4. GIGA-564 depletes intratumoral T regulatory cells within the tumor microenvironment, which enables the tumor-killing activity of cytotoxic T cells. Results also show that GIGA-564 offers increased anti-tumor efficacy and reduced toxicity compared to the commercially available drug ipilimumab, a monoclonal antibody designed to work through CTLA-4 checkpoint inhibition. The Phase 1a/1b dose escalation and dose-expansion trial, expected to start in 2024, will evaluate GIGA-564 for the treatment of advanced solid tumors. The trial will be conducted by National Cancer Institute researchers in close partnership with the GigaGen team, as established in the recently signed CRADA between GigaGen and NCI, a part of the National Institutes of Health.

08:31 EST Pliant Therapeutics presents three posters on PLN-101095 - Pliant Therapeutics presented three posters highlighting PLN-101095, a novel inhibitor of integrins alphavbeta8 and alphavbeta1. These posters were presented as part of the 38th Annual Meeting of the Society for Immunotherapy of Cancer, SITC, held November 1 - 5, 2023. "Trial in Progress: Phase 1a Trial of PLN-101095, an Integrin alphavbeta8 and alphavbeta1 Inhibitor, as Monotherapy and in Combination with Pembrolizumab, in Treatment-resistant Patients with Advanced or Metastatic Solid Tumors." Pliant is conducting a first-in-human, open-label, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of PLN-101095 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors and documented disease progression after at least 3 months from the start of treatment with pembrolizumab, and with no other available effective treatment options. "Integrin alphavbeta1 is Expressed in Multiple Solid Tumor Types and Drives the Adhesion of Cancer Associated Fibroblast to Latent TGF-beta." Expression of alphavbeta1 protein was evaluated across a diverse set of human tumor tissues and cancer-associated fibroblasts to investigate its functional role in cancer biology. PLN-101095, a selective small molecule inhibitor of alphavbeta8 and alphavbeta1 integrins, was evaluated in combination with anti-mPD-1 on fibrotic markers in the EMT6 tumor model. PLN-101095 was shown to block the binding of cancer-associated fibroblasts to the TGF-beta latency-associated peptide in a dose-dependent manner. EMT6 tumor tissues treated with PLN-101095 and anti-mPD-1 showed a significant reduction in fibrotic markers compared to anti-alphavbeta8 and anti-mPD-1. PLN-101095 was also shown to effectively reduce the expression of the fibroblast activation marker alphaSMA in ex vivo-treated human breast tumor tissues. "Selective Targeting of Integrins alphaVbeta8 and alphaVbeta1 within the Dynamic Ecosystem of Pancreatic Cancer to Improve the Overall Anti-tumor Response." PLN-101095, a selective small molecule inhibitor of alphavbeta8 and alphavbeta1 integrins, was assessed in preclinical models of pancreatic ductal adenocarcinoma. PLN-101095 was shown to decrease primary tumor growth, improve chemosensitivity in metastatic PDA with gene expression changes associated with favorable immune response and improved prognosis. Results showed that selective targeting of alphavbeta8 and alphavbeta1 with PLN-101095 or alphavbeta1 signaling with PLN-76104 potently inhibited primary tumor growth, spread and improve chemotherapy response in models of PDA.

08:28 EST HUB Security forecasts over $10M in new contracts in 2024 - HUB Cyber Security has signed a letter of intent for a financing and services agreement and strategic collaboration agreement with Blackswan Technologies, a top-tier enterprise AI company based in the United States. This strategic alliance heralds the commencement of a project in partnership with one of the Big4 Professional Services firms and their esteemed end customer, a globally renowned major banking group. The two companies are exploring the possibility of a potential merger. This collaboration, emphasizing digital transformation, is bolstered by Hub Security's expertise in cyber protection. Together, the two companies aim to revolutionize the banking sector across various regulatory domains. The primary objectives include streamlining operations, reducing ownership costs, and eliminating the need for data lakes and ETL processes. Hub Security's cutting-edge solutions will provide an additional layer of protection to critical processes, ensuring the security of the customer's most valuable assets. The collaboration will integrate Hub Security's protection of critical processes and its "Crown Jewels" asset protection. The initial contract would require Hub Security to provide $3.5 million in financing and is anticipated to make a substantial contribution of over $10 million to Hub Security's revenue in the fiscal year 2024, with expectations of further growth in the subsequent years.

08:27 EST Keystone Dental announces market launch of Nexus Connect - Keystone Dental Holdings announceds the market launch of Nexus Connect, a unique software system that utilizes proprietary technology and a machine-learning model to analyze implant scans performed with an intraoral scanner. The system employs proprietary 3D computer vision algorithms and geometric processing to detect Nexus Scan Gauges, segment them from tissue, and calculate their positions to ensure the captured data can proceed to prosthetic design. The analysis mechanism is a mathematical regression model based on thousands of completed real-world cases enabling immediate scan data results at the source of capture.

08:26 EST Cellares, Cabaletta Bio team to evaluate CABA-201 manufacturing on Cell Shuttle - Cellares, the first Integrated Development and Manufacturing Organization IDMO dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, announced Cabaletta will evaluate Cellares' automated manufacturing platform, the Cell Shuttle, through Cellares' Technology Adoption Partnership TAP program. As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of CABA-201, Cabaletta's clinical-stage fully human CD19-CAR T cell product candidate, using the Cell Shuttle. manufacturing in order to meet the potential demand from patients," said Gwendolyn Binder, Ph.D., President of Science and Technology at Cabaletta. "Cellares has made impressive progress with their automated cell therapy manufacturing capabilities. Their dedication to deploying these technologies at scale aligns well with our goal of bringing potentially transformative therapies to patients with autoimmune diseases." "This partnership enables us to leverage the unique capabilities of our Cell Shuttle platform to accelerate the production of CABA-201, Cabaletta Bio's innovative CD19-CAR T product candidate," said Fabian Gerlinghaus, CEO of Cellares. "Through our Technology Adoption Partnership program, we aim to fully automate all cell therapy manufacturing processes, thereby bringing us a step closer to potentially delivering CAR T cell therapies for patients with a broad range of autoimmune diseases. Together, we're not just enhancing manufacturing efficiency, but also fostering an environment that can facilitate the rapid advancement of life-altering therapies."

08:24 EST Vertex partners with Shopify to streamline global tax compliance - Vertex (VERX) its partnership with Shopify (SHOP), a provider of essential internet infrastructure for commerce. This partnership will enable enterprise merchants using the Shopify Tax Platform for business-to-business and business-to-consumer sales to automate tax calculation and compliance on a global scale. "Our goal is to help organizations transform their business operations to deliver a unified commerce experience," said Vertex Chief Commercial Officer, Chris Jones. "With the integration of Vertex solutions, enterprise retailers using Shopify can help ensure that tax is applied accurately and consistently regardless of how, when or where their customers transact."

08:21 EST Equillium announces data from Phase 1b EQUALISE study presented at ASN - Equillium announced that data from the Type B portion of the EQUALISE study in lupus nephritis patients was presented at the annual meeting of the American Society of Nephrology or ASN. The data highlights that subjects had high complete and partial response rates with rapid and deep reduction in urine protein creatinine ratio or UPCR, when itolizumab was added to mycophenolate mofetil, MMF, and corticosteroids. "The presentation at ASN represents current data from the EQUALISE study, which includes all but the last patient in the follow up period," said Bruce Steel, chief executive officer at Equillium. "We are encouraged that we continue to see clinically meaningful response rates, particularly in these highly proteinuric subjects. While the study is largely complete, we plan to deliver the full data package to Ono Pharmaceutical under the terms of our strategic partnership in early 2024." ...The Type B portion of the EQUALISE study in patients with active proliferative LN apLN is evaluating the safety, tolerability and clinical activity of subcutaneous delivery of itolizumab. Patients must present with greater than 1 gram of proteinuria and have a recent kidney biopsy showing ISN/RPS class III or IV apLN to be eligible for the study. During the 24-week treatment period, patients receive a subcutaneous dose of 1.6 mg/kg every two weeks, with follow up out to 36 weeks. Consistent with standard of care, patients on study also receive 2-3 g/day of mycophenolate mofetil/mycophenolic acid and patients may receive pulse systemic corticosteroids that are rapidly tapered.

08:20 EST Belite Bio presents results from a 24-month, Phase 2 study of Tinlarebant - Belite Bio presented final data from a 24-month, Phase 2 study of Tinlarebant in adolescent STGD1 at the American Association of Ophthalmology Annual Meeting. "Tinlarebant's final Phase 2 results represent a significant milestone for Belite Bio and provide additional foundational support for the work being conducted across our trials," said Dr. Tom Lin, Chairman and CEO of Belite Bio. "The final Phase 2 data continue to demonstrate Tinlarebant's safety profile and show a sustained lower DDAF lesion growth compared to ProgStar participants over the two-year treatment period. We hope to see similar data in the ongoing Phase 3 DRAGON study, further supporting Tinlarebant as a promising oral treatment for STGD1 patients." Key study findings: Tinlarebant was safe and well-tolerated with no withdrawals due to adverse events. Retinal imaging showed that 5 of 12 subjects remained free of atrophic retinal lesions after 24 months of Tinlarebant treatment. A comparison of the 24-month DDAF lesion growth between Tinlarebant-treated subjects and ProgStar participants possessing similar baseline characteristics showed a sustained lower DDAF lesion growth in Tinlarebant-treated subjects over the 24-month treatment period. Visual acuity was stabilized in majority of subjects during the study with a mean loss of five letters following 24 months of treatment.

08:19 EST IN8bio presents biologic correlative data from INB-200 Phase 1 trial - IN8bio presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting newly diagnosed glioblastoma multiforme in a poster presentation at the Society for Immunotherapy of Cancer's, SITC, 38th Annual Meeting. "Gamma-delta T cells are important in immune responses and their high levels are known to correlate with improved survival outcomes. Efficient immune reconstitution is pivotal for favorable outcomes in cancer patients. This new analysis sheds light on how our DeltEx DRI gamma-delta T cell approach may induce durable persistence and immune responses," said William Ho, Co-founder and CEO. "These important insights will help inform the ongoing development of our DeltEx DRI therapies across a variety of solid and hematological tumors.

08:18 EST Wallbox and Bidirectional Energy selected for proposed CEC REDWDS grant - Wallbox announced a partnership with Bidirectional Energy, a bidirectional EV energy management software platform, that has culminated in both companies being selected to receive significant funding from the highly competitive CEC REDWDS grant. The companies plan to offer Wallbox's second-generation DC bidirectional charger, Quasar 2, with the Bidirectional Energy EV charger management platform, starting in the first half of 2024. The California Energy Commission's Clean Transportation Program provides up to $100M in annual funding to support innovation and accelerate the development and deployment of advanced transportation and fuel technologies throughout the state. The REDWDS (Responsive, Easy Charging Products with Dynamic Signals) grant accelerates the development and deployment of easy-to-use charging products, which helps customers manage electric vehicle charging and respond to dynamic grid signals. In a highly competitive process, Bidirectional Energy and Wallbox have been proposed recipients for awards of $2.2M in Phase 1 funding by the CEC Clean Transportation Program. When the awards are confirmed, the partnership between Bidirectional Energy and Wallbox will be able to deploy Quasar 2 bidirectional chargers in California residential homes, as well as offer installation solutions via COIL, a Wallbox company. Through the Bidirectional Energy platform, EV owners can potentially save money on their monthly utility bill as well as benefit from various utilities' vehicle-to-grid programs, all while their EV is parked at home. The V2X vehicle-to-everything system can also keep the lights on when the grid goes down, providing extra resilience to homeowners. If the project is successful, additional funding will be made available through a second phase to continue deploying bidirectional chargers across California for an additional three years.

08:17 EST Taboola enhances generative AI technology for advertisers - Taboola announced new advancements in its Generative AI technology for advertisers. With Taboola Generative AI AdMaker, advertisers can instantly adjust existing creative assets, such as replacing backgrounds or generating image variations, significantly speeding the time it takes to launch their campaigns. "Taboola's Generative AI technology continues to unlock more benefits that advertisers are looking for, such as driving more customers and improving efficiency for running campaigns," said Adam Singolda, CEO at Taboola. "We're seeing great examples of advertisers already tapping into our Generative AI technology to get up and running faster with creative and copy that in some cases outperforms their evergreen campaigns. With AdMaker, we're making it easier than ever for advertisers to test and launch variations on creative, which is an essential part of producing images that resonate especially with seasonal campaigns."

08:16 EST Cibus notes European draft report on regulation of plants obtained from NGTs - Cibus acknowledged the European Parliament's draft report on the European Commission proposal for regulation of plants obtained from New Genomic Techniques. The proposal is a result of a European Commission study, requested by EU Member States, which concluded that EU GMO legislation was not fit for purpose in relation to applications of NGTs in plants. NGTs include a variety of gene editing techniques leading to genetic changes classed as targeted mutagenesis and cisgenesis. The proposal describes a category of NGTs producing modifications that could be obtained in nature or by conventional breeding. These are determined to be 'Conventional-like' and would be regulated in the same way as conventional varieties. The proposal was adopted by the EU College of Commissioners at their meeting on July 5th, 2023 and was passed to the European Parliament and the Council of the European Union for review. "We welcome the proposal from the European Commission and the ambitious goals outlined by the European institutions," said Tony Moran, Cibus Senior Vice President of International Development and Government Affairs. "Europe initiated discussions on these techniques in 2008 but has since been overtaken by a growing number of countries that are benefitting through more enabling legislation. The proposed regulations improve alignment with EU trading partners and a timely adoption would be a significant boost for innovators particularly in academia and small and mid-sized enterprises who are actively developing NGT products that could contribute to a sustainable EU agri-food system." The draft report, published by the European Parliament Committee on the Environment, Public Health and Food Safety on 19th October, represents the first stage of their review and is a significant step in the passage of the proposal through the EU legislative procedure. The draft report recognizes the Commission proposal as a solid starting point and recommends further improvements to ensure the best possible usage of the techniques in the EU. These include clarification of the criteria for conventional-like NGT plants, freedom of choice for organic farmers to use NGTs plants and ensuring a science-based verification procedure . The Committee is aiming to finalise its report by January 2024 ahead of a vote in a plenary session of the European Parliament in February.

08:14 EST Arena Group to combine with Bridge Media - Arena Group announced that it has signed a definitive agreement under which the company will combine with Bridge Media, a wholly owned subsidiary of Simplify Inventions. In connection with the business combination, 5-Hour International will purchase $25M of common stock of the combined company and The Hans Foundation, will purchase $25M of preferred stock of New Arena. The Arena Group and Simplify previously announced the signing of a binding letter of intent between the parties on August 14. The proposed transaction is expected to expand the reach and capabilities of The Arena Group and provide it with growth capital while also reducing its debt and extending the terms on its existing debt facilities, further strengthening and fortifying The Arena Group's balance sheet. Under the terms of the agreement, The Arena Group stockholders will receive one share of common stock of New Arena for each share of The Arena Group common stock they own. Immediately following the proposed transaction, Simplify and 5-Hour are expected to hold 65% of all outstanding shares of New Arena common stock. Simplify has also agreed to purchase, from time to time at Arena's election, up to $20M of additional common equity in New Arena, for a period of one year following the closing date of the business combination, to be used for operations and growth. Pursuant to the proposed transaction, the existing assets of The Arena Group will be combined with the video programming, distribution, and production assets of Bridge Media Networks, including Bridge Media Networks' two 24-hour networks, NEWSnet and Sports News Highlights, as well as the automotive and travel properties Driven and TravelHost. In addition, The Arena Group will receive a five-year guaranteed advertising commitment of approximately $60M aggregate value from a group of consumer brands also owned by Simplify, including 5-hour Energy. The Arena Group intends to use a portion of the cash proceeds to reduce its debt by $26M from current levels. The board of directors of The Arena Group received a fairness opinion from Current Capital Securities in connection with the proposed business combination. The proposed transaction is expected to close in the fourth quarter of 2023 or first quarter of 2024 subject to the approval of The Arena Group's stockholders, the receipt of any required regulatory approvals and certain other closing conditions. Upon completion of the transaction, New Arena is expected to trade on the NYSE American under the ticker symbol (AREN).

08:13 EST Caribou Biosciences appoints Sundar Jagannath to Scientific Advisory Board - Caribou Biosciences announced the appointment of Sundar Jagannath, MD, to its scientific advisory board. With four decades of experience, Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma, and he is the director of the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and professor of medicine, hematology and medical oncology, at Mount Sinai School of Medicine, New York.

08:12 EST Post Holdings' President, CEO Vitale to take medical leave of absence - Post Holdings announced that President and Chief Executive Officer Robert Vitale will be taking an unexpected medical leave of absence. At this time, it is too soon to know the course of treatment and timing of recovery. Consistent with Post's established emergency succession protocol, Post's Board of Directors has named Jeff Zadoks, currently Post's Executive Vice President and Chief Operating Officer, as interim CEO while Vitale is on leave. Zadoks has a long history with Post working closely with Mr. Vitale and the Board, serving in various roles at Post since 2011.

08:11 EST Bombardier announces cash tender offer for certain senior notes - Bombardier announced the commencement of a tender offer to purchase for cash up to $110,000,000 aggregate purchase price of its outstanding Notes of the two series listed in the table below provided that the Company will only accept for purchase its 7.125% Senior Notes due 2026 having an aggregate purchase price of up to $75,000,000 and its 7.875% Senior Notes due 2027 having an aggregate purchase price of up to $35,000,000. The Tender Offer will be financed by the amounts raised in Bombardier's offering of new Senior Notes. The Tender Offer is being made pursuant to an Offer to Purchase dated November 6, 2023.

08:10 EST New Fortress Energy charters Petrobras' FSRU Energos Winter starting December 20 - New Fortress Energy (NFE)announced that it has executed a definitive agreement to charter the Floating Storage and Regasification Unit, FSRU, Energos Winter from Petrobras (PBR) starting in December 2023. The FSRU Energos Winter will be immediately deployed to Terminal Gas Sul, NFE's newest LNG import terminal in Santa Catarina, Brazil which will start commercial operations ahead of schedule in January 2024. "We are extremely pleased to reach this agreement with Petrobras and begin operations at the TGS terminal in Santa Catarina, Brazil ahead of schedule in January 2024. The TGS terminal is a unique, high-growth opportunity for NFE, as connection to the pipeline system in south Brazil offers a diverse and near-term set of opportunities across power and gas supply," said Andrew Dete, Managing Director of New Fortress Energy. The Energos Winter will be sub-chartered by NFE through the remaining term of the Petrobras charter with Energos infrastructure and then direct-chartered by NFE on a long-term basis with Energos. This will enable NFE to commence commercial operations at TGS in January 2024 and continue uninterrupted service on a long-term basis. Energos Infrastructure, the owner of the Energos Winter, is owned 80% by funds managed by Apollo and 20% by NFE. The transactions described in this press release are subject to customary terms and conditions

08:09 EST Bombardier announces launch of new issuance of senior notes - Bombardier announced that it has launched an offering of US$500 million aggregate principal amount of new Senior Notes due 2030. Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, to fund the redemption of all of its outstanding 7.50% Senior Notes due 2025, of which there is $380 million aggregate principal amount outstanding on the date hereof, to finance the offers to purchase up to $110 million aggregate purchase amount of its outstanding 7.125% Senior Notes due 2026 and 7.875% Senior Notes due 2027, of which there is $1,200 million aggregate principal amount outstanding of the 2026 Notes and $1,892 million aggregate principal amount outstanding of the 2027 Notes on the date hereof, and/or for the repayment of other indebtedness, and for the payment of accrued interest and related fees and expenses. Consummation of the offering of the New Notes, the 2025 Notes Redemption and the 2026-2027 Tender Offer are subject to market and other conditions, and there can be no assurance that Bombardier will be able to successfully complete these transactions on the terms described above, or at all. The 2025 Notes Redemption and the 2026-2027 Tender Offer are subject to certain conditions, including the completion of the offering of the New Notes prior to December 6, 2023, as it relates to the 2025 Notes Redemption, and prior to November 24, 2023, as it relates to the 2026-2027 Tender Offer.

08:08 EST Bombardier announces conditional notice of redemption of senior notes - Bombardier has issued a conditional notice of redemption for all of its outstanding 7.50% Senior Notes due 2025. As set forth in the conditional notice of redemption issued today in respect of the Notes, the redemption date is December 6, 2023, and the redemption price is 100% of the principal amount redeemed, plus accrued and unpaid interest. The redemption of the Notes is subject to and conditioned upon Bombardier completing a new offering of debt securities in the aggregate principal amount of not less than US$500 million before the Redemption Date; however, Bombardier may delay or waive this condition in its sole and absolute discretion.

08:07 EST Newmont completes acquisition of Newcrest Mining - Newmont (NEM) announced it has completed the acquisition of Newcrest Mining (NCMGY). "Today marks a historic milestone in our company and the industry with the successful completion of this transformational acquisition of Newcrest by Newmont," said Tom Palmer, Newmont's president and CEO. "Our attention now turns to safely, efficiently, and responsibly integrating Newcrest's assets and people into Newmont's proven operating model, so we can accelerate the delivery of our value-focused strategy for all our stakeholders."

08:04 EST Pixelworks continues collaboration with MediaTek - Pixelworks announced that MediaTek has adopted the company's visual processing Pro Software solution in its new Dimensity 9300 flagship SoC for smartphones. Pixelworks' professional color calibration solution significantly enhances the color display capabilities of the Dimensity 9300 5G chipset to deliver smoother picture quality and more accurate color display for pictures, videos and gaming animations on mobile devices, resulting in improved gaming visual experiences for end users.

08:00 EST Fury Gold Mines announces results from drill holes at Percival Main - Fury Gold Mines announced results for the first five 2023 core drill holes from the Percival Main prospect, located 14 kilometers east of the high-grade Eau Claire gold deposit in the Eeyou Istchee Territory in the James Bay region of Quebec. Drill hole 23KP-015 targeted a 70 meterstep out from the 2022 drilling on the eastern flank of the known Percival Main mineralization and intercepted 279 g/t Au over 1.5 m, 5.0m of 2.68 g/t gold and 7.5m of 2.31 g/t gold. Drill hole 23KP-015 is on the easternmost section completed to date at Percival Main which remains open in all directions. Three drill holes targeted the westerly continuation of the high-grade intercept reported from drill hole 22KP-008. These drill holes intercepted 22.5m of 0.52 g/t gold from 23KP-009; 19.5m of 0.66 g/t gold from 23KP-010 and; 52.5m of 0.34 g/t gold from 23KP-011. Results for a single hole testing the easterly continuation of the same 2022 intercept encountered additional broad zones of mineralization including 48.5m of 0.86 g/t gold, 16.5m of 1.42 g/t gold, including 11.55 g/t gold over 1.5m, and 14m of 1.09 g/t gold from 23KP-012. Notably, the intercepts reported from drill hole 23KP-012 occur approximately 125m down plunge to the east of the reported 2022 drill intercept of 8.05 g/t gold over 13.5m. "The Percival Prospect has been an important focus for Fury given its potential for additional discovery. Today's results are exciting in that they represent the third highest-grade intercept reported for the entire Eau Claire project and the furthest step out to the east, giving us renewed confidence in our geological assumptions," commented Tim Clark, CEO of Fury. "Looking forward, we have an additional 3,700m of drill results still pending from Percival, including two holes targeting biogeochemical anomalies further east of Percival Main along the highly prospective Cannard Deformation Zone. As for the Eau Claire resource, our drill remains in operation with additional results expected in the coming weeks and months."

07:56 EST Laser Photonics to announce maritime laser cleaning commercial - Laser Photonics Corporation has announced it will be releasing a first of its kind commercial introducing the company's Handheld Marine Application Rust Laser Inhibitor, MARLIN, line of laser cleaning products to the maritime industry. 'To the best of our knowledge, this will be the first laser cleaning commercial of its kind to be aired to the public,' said Wayne Tupuola, CEO of Laser Photonics. 'We are excited to introduce the power of our cutting-edge laser cleaning equipment to marina operators, boatyard workers and ship owners.'

07:54 EST ParkerVision announces oral arguments in Qualcomm case - ParkerVision (PRKR) is scheduled to appear at the United States Court of Appeals for the Federal Circuit this morning for oral arguments in ParkerVision v. Qualcomm (QCOM). ParkerVision filed its notice of appeal in April 2022 following rulings by the U.S. District Court in the Middle District of Florida in the Company's patent infringement case against Qualcomm that resulted in the court closing the case file and terminating ParkerVision's right to a jury trial. ParkerVision CEO Jeffrey Parker commented, "I have been contacted by many shareholders with questions about the appealed rulings in this case. All of the legal briefs filed with the CAFC in this case are available on our website at https://parkervision.com/pvcase-jrk-2/. In addition, the Company has posted an overview of the district court rulings that are subject to this appeal, along with a summary of the underlying facts, evidence and arguments presented in our briefs to the CAFC, and the expected impact of each of these rulings on the case. This document can be found at Case Appeal Overview.

07:52 EST Signal Gold amends Nebari credit facility - Signal Gold has executed an amendment to its credit facility dated February 16, 2023 with Nebari Gold Fund 1 LP, Nebari Natural Resources Credit Fund I LP, and Nebari Natural Resources Credit Fund II LP. Under the terms of the amendment, the interest capitalization period in the Credit Agreement shall be extended by six months from March 31, 2024 to September 30, 2024. "Signal Gold is pleased to announce this amendment to its credit agreement with Nebari, a key partner in our continued advancement of the Goldboro Project in eastern Canada. While junior development companies are experiencing challenging equity markets, this amendment provides the Company with the near-term flexibility to continue to responsibly progress the Goldboro Project by focusing on key value-add initiatives including the advancement of key Project permit applications and continued exploration and regional work on our significant exploration land package to demonstrate the gold camp potential of the Goldboro Gold District," said Kevin Bullock, President and CEO, Signal Gold Inc.

07:51 EST Else Nutrition announces United Kingdom market launch - Else Nutrition announced the launch of its highly acclaimed, Plant-Based Complete Nutrition Toddler Drink in the United Kingdom, cementing its presence through partnerships with leading UK distributors. This milestone is a direct result of the Company's strategic initiatives to expand into new international markets and marks the Company's first foray into the multi-billion-dollar European market. "Entering the UK is a game-changer for us and for health-aware families, as we introduce our products both online and in stores," said Hamutal Yitzhak, CEO of Else Nutrition. "The UK represents our first entry into the lucrative European market, and we expect to enter additional European countries in the near term. Moreover, Europe is an ideal market for our products given consumer preferences and trends towards healthy and nutritious plant-based options, especially for their children. Feedback from our partners has been overwhelmingly positive, and we anticipate sharing key upcoming milestones as we progress."

07:50 EST Biogen appoints Patolawala to board of directors - Biogen (BIIB) announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company (MMM), to the Company's Board of Directors, effective January 1, 2024. As an accomplished financial executive, Patolawala is qualified as an Audit Committee financial expert and may be asked to serve as a member of the Board's Audit Committee.

07:49 EST Amesite announces partnership expansion with Benedict College - Amesite announces it has expanded its partnership with Benedict College, building on their successful pilot program through the NAFEO-Amesite Alliance. The Alliance is offering this program to NAFEO's approximately 180 associated member colleges and universities, in order to expand these institutions' capability to deliver professional learning, and drive impact and revenue. This partnership expansion follows Amesite's recently announced risk-free offering for higher education. The offering includes an array of benefits including ease of adoption, revenue generation, and brand leverage. The offering enables higher education institutions to offer professional education and workforce training programs at accessible price points, that enable learners to advance their careers. "We are thrilled that Benedict is taking the step with us to drive educational impact and revenue," said Amesite CEO, Dr. Ann Marie Sastry. "With our streamlined, no-risk purchase offer - our customers are able to deliver a vast range of learning programs through their branded platforms at an unparalleled pace."

07:48 EST Hilton Grand Vacations to acquire Bluegreen Vacations for $1.5B - Hilton Grand Vacations (HGV) announced that it has entered into a definitive agreement to acquire Bluegreen Vacations (BVH) for $75 per share in an all-cash transaction, representing total consideration of approximately $1.5B, inclusive of net debt. The acquisition is also expected to include an exclusive marketing agreement with Bass Pro Shops and its base of outdoor lifestyle enthusiasts. Expanding on Bluegreen Vacations' existing relationship, HGV also announced today that it has signed a new 10-year exclusive marketing agreement with Bass Pro Shops. Under the terms of the agreement, Bluegreen Vacations stockholders are expected to receive $75 in cash for each share of Bluegreen Vacations. The all-cash transaction values Bluegreen Vacations at approximately $1.5B, inclusive of net debt. The transaction, which was unanimously approved by the board of directors for both companies, is expected to close during the first half of 2024 and is subject to customary closing conditions and regulatory approvals. HGV's management team, including president and CEO Mark Wang, chief financial officer Dan Mathewes, and chief operating officer Gordon Gurnik, will continue to serve in their current roles upon transaction close.

07:47 EST InflaRx announces first patient dosed in Phase III trial - InflaRx N.V. announced that the first patient has been dosed in its Phase III study investigating the efficacy and safety of vilobelimab in ulcerative PG, a rare neutrophilic and inflammatory skin disease characterized by destructive, painful cutaneous ulcers. "We are pleased that the first patient has been dosed in the U.S. in our pivotal Phase III study with vilobelimab for the treatment of ulcerative pyoderma gangrenosum. There are currently no approved treatments for this debilitating disease in either the U.S. or Europe, and therefore, there remains a high unmet medical need for these patients," said Dr. Camilla Chong, MD, Chief Medical Officer of InflaRx. "The Phase III study builds on our promising Phase II clinical results, and we look forward to the continual collaboration with external experts with the ultimate goal of helping patients that are suffering from this devastating condition." The Phase III clinical study is designed to enroll patients worldwide, including countries such as the U.S., countries in Europe, and Australia. The multi-national, randomized, double-blind, placebo-controlled trial has two arms: one arm receiving vilobelimab plus a low dose of corticosteroids and another arm receiving placebo plus the same low dose of corticosteroids. In both arms, corticosteroid treatment will be initiated on day 1 and will be tapered off within the first 8 weeks of the trial. The primary endpoint of the study is complete closure of the target ulcer at any time up to 26 weeks after initiation of treatment.

07:45 EST Starbucks to raise pay for certain U.S. retail hourly partners on January 1 - Sustained investment in retail partner pay remains a priority. Starbucks moved the wage floor for all U.S. retail hourly partners to $15 per hour in 2022 and has continued to add incremental increases, while recognizing and rewarding tenure. Starting with competitive pay - Starbucks provides U.S. hourly retail partners an average wage of nearly $17.50 per hour, a wage range between $15 and $24 per hour and a total compensation, with benefits, of approximately $27 per hour. Effective January 1, eligible U.S. retail hourly partners will see an incremental pay increase come to life, with at least a 3% increase and differentiated pay for eligible tenured partners. Eligible partners with 2-5 years of service will get at least 4% and those with 5 or more years of service will get at least 5%.

07:43 EST Lithium Ionic reports drill results from Bandeira Project - Lithium Ionic reports additional results from an ongoing drilling program at the Bandeira Project, located in northern Minas Gerais State, Brazil. The Company is rapidly advancing Bandeira, situated within the emerging "Lithium Valley", where two lithium producers currently operate. These results form part of a large 50,000-metre drill program underway for H2 2023, which is focused on expanding and upgrading existing mineral resource estimates to support a planned Feasibility Study, as well as grow the known mineralization at other prospective regional targets. Bandeira Drill Intercept Highlights: 1.64% Li2O over 13.5m, including 2.06% Li2O over 7.8m, as well as 1.78% Li2O over 5.8m; 1.37% Li2O over 10.4m and 1.65% Li2O over 4.3m; 2.18% Li2O over 5.8m; 1.95% Li2O over 5.7m; 1.50% Li2O over 6.7m; 3.57% Li2O over 2.4m, 1.54% Li2O over 4.7m and 1.84% Li2O over 3.3m; 1.57% Li2O over 5.0m; 1.32% Li2O over 5.2m; 1.69% Li2O over 4.0m and 1.78% Li2O over 3.8m; 1.46% Li2O over 4.4m; Blake Hylands, P.Geo., Chief Executive Officer of Lithium Ionic, commented, "The multiple intercepts of significant widths, and above our resource grade, announced today demonstrates the potential for the mineral resources at Bandeira to quickly keep expanding and improving. We believe this additional infill drill data will support significant resource conversion, ultimately reinforcing and potentially enhancing the excellent results from our PEA."

07:40 EST Acumen, Halozyme enter global collaboration, license agreement - Acumen Pharmaceuticals (ABOS) announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics (HALO). The collaboration will provide Acumen access to Halozyme's ENHANZE drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme, for the development of a subcutaneous formulation of ACU193, the first clinical-stage AbetaO-targeting antibody. ENHANZE has been commercially validated in seven approved therapies, with global collaborations covering more than 60 therapeutic targets. Acumen intends to explore using ENHANZE with ACU193 and plans to initiate Phase 1 development in human subjects in mid-2024 to compare the pharmacokinetics of a subcutaneous form of ACU193 to the intravenous form. Acumen recently completed the Phase 1 INTERCEPT-AD trial in patients with early AD, which demonstrated robust, dose dependent target engagement for ACU193 and additionally produced amyloid plaque reduction following three administrations of ACU193 at 25 mg/kg or 60 mg/kg. At or near a three-month timepoint, ACU193 reduced amyloid plaque to a comparable level as that observed with administration of LEQEMBI. Under the terms of the agreement, in return for an upfront payment to Halozyme and other considerations, Acumen will receive non-exclusive rights to ENHANZE. Acumen is obligated to make future payments to Halozyme, subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also be entitled to receive royalties on sales of commercialized medicines using the ENHANZE technology.

07:36 EST 22nd Century remains 'committed' to exploring wide range of alternatives - On September 5, 2023, the Company announced its intent to explore strategic alternatives, enlisting TD Cowen as its advisor, in an effort to maximize shareholder value. While the initial focus was primarily on 22nd Century Inc.'s tobacco portfolio, the Company subsequently received indications of interest regarding its other assets, in addition to tobacco. The Company continues to be committed to the process of exploring a wide range of strategic, operational, and financial transactions and alternatives.

07:35 EST Comvest Partners to sell Systems Control to Hubbell in transaction, no terms - Comvest Partners announces the execution of a definitive agreement to sell Systems Control to Hubbell, a manufacturer of utility and electrical solutions. Systems Control has been a portfolio company in Comvest's private equity strategy since 2018. The transaction is expected to close by the end of the year. "This successful outcome highlights Comvest's expertise in helping companies achieve their growth objectives as well as our investment leadership in the infrastructure services space. We are excited for the Company's future as part of Hubbell," added Maneesh Chawla, a Managing Partner at Comvest. Brad Lebouef, Chief Executive Officer at Systems Control, said, "Comvest supported System Control's vision for growth throughout our partnership, providing both capital and invaluable support key to the achievement of our desired growth milestones. We are appreciative of Comvest's stewardship and look forward to our next chapter with the terrific team at Hubbell."

07:33 EST Actinium Pharmaceuticals' Actimab-A shows immunotherapy potential - Actinium Pharmaceuticals announced data presented at Society of Immunotherapy of Cancer Annual Meeting further supporting Actimab-A, the company's clinical stage targeted radiotherapeutic comprised of the CD33 targeting antibody lintuzumab and the Actinium-225 alpha-particle emitting payload. The poster highlighted Actimab-A's ability to target and deplete myeloid-derived suppressor cells - MDSCs -, which uniformly express CD33. MDSCs are a cell population of interest as they remodel the tumor environment and promote immune evasion. Actinium believes Actimab-A has the potential to be used in combination with immunotherapy, including immune checkpoint inhibitors, to enhance antitumor immunity via targeted MDSC depletion.

07:31 EST Helius Medical announce study results on PoNS therapy - Helius Medical Technologies announced the publication of a white paper demonstrating that rehabilitative treatment with the Portable Neuromodulation Stimulator, PoNS, can drastically improve return-to-work outcomes for patients suffering from TBI. The report, entitled "Evaluating the Real-World Impact of PoNS Therapy on Return-to-Work Outcomes in Individuals on Long-Term Disability due to Traumatic Brain Injury," was co-sponsored by Pacific Blue Cross and HealthTech Connex, and performed at the Surrey Neuroplasticity Clinic. Key findings of the study include: Five out of nine participants returned to work; Four of those five returned to their prior occupations full-time for at least six months; Six of the nine study participants experienced a clinically significant ; improvement in balance and gait; Eight of nine said that balance and gait was no longer a barrier to return to work; Three of six participants who indicated headaches were a barrier to work saw a reduction in the severity of their headaches; PBC estimated that the five individuals who returned to work saved the provider approximately $1.6 million in long-term disability claims

07:29 EST Marimaca Copper announces results from Phase 6 metallurgical program - Marimaca Copper announced results of the Phase 6 Metallurgical testing program for the Company's flagship Marimaca Oxide Copper Project, located in northern Chile. The Phase 6 program was designed to evaluate leaching conditions to optimize acid consumption, recoveries and leaching efficiency to be incorporated into the ongoing Definitive Feasibility Study. Highlights: Comprehensive 5 column-test program evaluating the impact of curing, leaching rates and acid concentration in solution on acid consumption, recoveries and impurities generation; Significantly improved acid consumption based on optimization of leaching conditions; Net acid consumption of 30.6kg/t from experimental samples - an approximate 25% reduction from the 40.6kg/t derived from previous metallurgical campaigns; Provides further confidence in expected acid consumption with clear potential to enhance operating cost profile for the DFS; Confirms average copper recovery of 74.9% - in-line with previous results from metallurgical campaigns; Flexibility for further reductions in acid consumption with relatively low recovery losses; Program completed with recycled sea-water sourced from Marimaca's intended water supplier under its water option agreement to accurately reflect process water to be utilized at the Project; Further de-risking of the Marimaca metallurgy - allows for improved predictability of metallurgical performance during operations; Results will be incorporated into the final geo-metallurgical model to be utilized in the DFS which will define, at high resolution, the metallurgical performance of each ore-feed type in the DFS; Results demonstrate the self-regulation of impurities in the leaching cycle which allows for simple SX-EW process design and capital efficiency for the planned DFS. Hayden Locke, President and CEO of Marimaca Copper, commented: "We are pleased with the Phase 6 metallurgical results and particularly the implications for acid consumption optimization in the DFS and in future operations. Acid consumption is a key component of our operating costs, and fluctuations in acid price were identified as a core external factor in our projected operating margins as we move towards first copper. The results from this program show, firstly, that our base case assumptions, with respect to acid consumption, can be materially reduced via simple changes to our operational approach with no significant impact to our expected recoveries. Secondly, the testing highlights that we have further flexibility to reduce acid consumption, with relatively small recovery losses. From my perspective, this is the most important outcome from the testing, because it allows us to make operational changes to preserve margin and cashflow during periods of high acid prices, which increases the resilience of the Project to external shocks. The Marimaca Project continues to demonstrate unique positioning in the copper development space. We are excited to move through the final development milestones as we rapidly advance toward first copper."

07:26 EST Zentalis announces updated data from Phase 1 trial of azenosertib - Today, the Company announced an updated analysis of the ongoing Phase 1 clinical trial of azenosertib as a monotherapy in solid tumors, which continued to show anti-tumor activity with intermittent dosing. In the same population of 19 platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients that were included in the data reported on June 6, 2023, the objective response rate was 37%. Median follow-up has increased by nearly 5 months and the median progression free survival has increased to 6.5 months. With additional safety-evaluable patients and follow-up since June, azenosertib continues to demonstrate a favorable safety and tolerability profile that is similar to or better than approved ovarian cancer products, supporting its continued advancement.

07:24 EST ZyVersa Therapeutics announces article on inhibiting NLRP3 - ZyVersa Therapeutics announces publication of an article in the peer-reviewed journal, Ecotoxicology and Environmental Safety, demonstrating that inhibiting NLRP3 inflammasomes can attenuate kidney damage and dysfunction associated with the environmental pollutant, PM2.5. In the paper titled, "PM2.5 induces renal tubular injury by activating NLRP3-mediated pyroptosis," the authors conducted studies in a mouse model exposed to high concentrations of ambient PM2.5 for 12 weeks, and in a mouse kidney cell line. Following are key findings reported in the paper: PM2.5 exposure leads to kidney structural changes and functional impairment. Inflammasome NLRP3-induced Inflammation and pyroptosis were increased in PM2.5-exposed kidney tissues. Inhibiting the inflammasome NLRP3 pathway, including downstream caspase-1, rescued the kidneys from PM2.5-induced cell death. "The research published in the Journal, Ecotoxicology and Environmental Safety, reinforces other published data demonstrating that inhibiting NLRP3 inflammasomes can attenuate kidney damage and dysfunction of multiple causes, now including kidney damage associated with the environmental pollutant, PM2.5," commented Stephen Glover, ZyVersa's Co-founder, Chairman, CEO and President. "This research provides increasing support for inflammasome inhibition as a promising treatment option for kidney disease, a major health problem affecting over 35 million adults in the United States. ZyVersa is developing Inflammasome ASC inhibitor IC 100. Unlike NLRP3 inhibitors, designed to inhibit formation of one inflammasome to block initiation of the inflammatory cascade, IC 100 was designed to inhibit multiple types of inflammasomes and their associated ASC specks to uniquely block both initiation and perpetuation of damaging inflammation."

07:22 EST Telus CEO purchases 395,843 shares since beginning of the year - TELUS President and CEO Darren Entwistle has reaffirmed his commitment to TELUS' success by making significant share purchases this year. Since the beginning of the year through October 2023, he purchased 395,843 common shares for an aggregate purchase cost of approximately $10 million. Darren now holds a total of 800,000+ TELUS common shares.

07:21 EST TScan Therapeutics presents Phase 1 trial design for solid tumor program - TScan Therapeutics announced the presentation of six posters at the Society for Immunotherapy of Cancer 38th Annual Meeting. TScan's Phase 1 solid tumor clinical trial is designed to assess customized, multiplexed TCR-T as a way to overcome tumor heterogeneity and HLA loss of heterozygosity. First generation TCR-T, targeting single antigens, has shown encouraging response rates, but has often shown short durations of respons. TScan believes that its approach to multiplexing across targets and HLAs will result in increased response rates and increased duration of response. To make this possible, TScan is prospectively screening patients with melanoma, non-small cell lung cancer, head and neck cancer, cervical cancer, ovarian cancer, and anogenital cancers for target expression and the presence of intact HLA genes. Customized treatment is made possible by the Company's ImmunoBank, its repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types. TScan continues to prioritize populating the ImmunoBank to increase the number of addressable targets, thereby increasing the percentage of patients that are eligible to receive either singleplexed or multiplexed treatment. In the treatment protocol, each TCR-T is first tested as singleplexed therapy at two different dose levels to assess safety. Once a TCR-T has cleared dose level two, it becomes eligible to be combined with any other TCR-T that has also cleared dose level two. As additional Investigational New Drug Applications (INDs) for TCR-Ts are cleared by the FDA and enter the ImmunoBank, they will be incorporated into the same study and follow the same dose escalation scheme, enabling a rapid path to novel multiplexed therapies. Using TargetScan, TScan has identified a novel B*07:02-restricted epitope in the cancer/testis antigen MAGE-C2 as a promising target for TCR-T therapy. TScan is developing TSC-201-B0702, a TCR-T cell therapy that targets this epitope, with plans to file an IND by the end of the year. TCR-Ts targeting MAGE-C2 could potentially be used to treat up to 50% of melanoma patients, 25% of patients with head and neck cancers, and 50% of patients with NSCLC in the United States.

07:19 EST Paramount's Grassy Mountain receives notice to proceed from Oregon regulators - Post the receipt of the positive completeness determination announced on October 5th, Paramount Gold Nevada announced that the Oregon Department of Geology and Mineral Industries has issued the Notice to Proceed required to move Grassy Mountain into the next phase of permitting. Based on state regulations, it is expected that the DOGAMI will issue the final consolidated permit package within one year. Paramount President, COO and Director, Glen Van Treek commented: "The Notice is a critical milestone in securing the permits to build and operate Grassy. Paramount will continue to work collaboratively with the agencies as they move through the next important steps to achieving that goal." The complete permit package will include the Environmental and Socioeconomic Evaluation (currently underway by Stantec, a global leader in engineering, architecture and environmental consulting, contracted by DOGAMI, which is expected to be released in early 2024. The EE will serve as an additional resource to the agencies for their permit writing process.

07:18 EST StorageVault Canada to acquire four locations for $75.7M - STORAGEVAULT CANADA has agreed to acquire four locations from four vendor groups for an aggregate purchase price of $75,685,000, subject to customary adjustments. Three of the Acquisitions are arm's length and one for $45,000,000 is a related party acquisition with Access Self Storage as the Vendor for that Acquisition. It is anticipated that the Acquisitions will close before December 31, 2023. The assets are located in Nova Scotia, Quebec, Ontario and British Columbia. The aggregate purchase price is $75,685,000, subject to adjustments, and is payable with funds on hand and debt. The obligations of StorageVault to complete the Acquisitions are subject to conditions including, but not limited to: completion of agreement of purchase and sale, satisfactory due diligence and satisfactory environmental site assessment reports. The obligations of both StorageVault and the Vendors to complete the closing of the Acquisitions are subject to the satisfaction of other customary closing conditions and include, for the Related Party Acquisition, the acceptance of the TSX. None of the four Vendor group Acquisitions are conditional or contingent on the completion of the other Acquisition.

07:16 EST Lantronix appoints Awsare as President, CEO - Lantronix (LTRX) announced that Saleel Awsare will be joining Lantronix as President and CEO of the company, effective Nov. 20, 2023. Awsare comes to Lantronix from Synaptics (SYNA), a leading provider of semiconductor products worldwide, where he has most recently served as senior vice president and general manager of its Enterprise and Mobile Division, its largest division.

07:14 EST Instil Bio announces presentations on ITIL-306 data at SITC Meeting - Instil Bio reported two poster presentations at the SITC 2023 Annual Meeting demonstrating that its proprietary CoStimulatory Antigen Receptor platform enhances the activity of CD4+ T cells across multiple axes. TIL therapy utilizes a mixed population of tumor-reactive CD4+ and CD8+ T cells, with both populations of T cells able to drive tumor regression. CoStAR has previously been demonstrated to improve proliferation, secretion of soluble factors, and in vivo tumor control in preclinical studies with mixed populations of CD4+ and CD8+ T cells. New single-cell RNA sequencing data presented at the SITC 2023 Annual Meeting revealed enhanced gene signatures of activation and cytotoxicity in CoStAR-transduced CD4+ T cells, with significant increases in cytotoxic function of these CD4+ T cells in an in vitro cytotoxicity assay. These data suggest that CoStAR is able to endow CD4+ T cells with novel cell-killing capacity, potentially broadening the repertoire of tumor-killing TIL to include CD4+ T cells in addition to naturally cytotoxic CD8+ T cells. Additionally, CoStAR was demonstrated to enhance the secretion of soluble factors from CD4+ T cells to boost the proliferation and survival of companion CD8+ T cells. As CoStAR provides proliferative benefit to mixed populations of CD4+ and CD8+ T cells, these data demonstrate the importance of CD4+ CoStAR-T cells in supporting the proliferation of CD8+ CoStAR-T cells through the provision of soluble factors.

07:13 EST Ginkgo Bioworks and Xwell expand work with CDC to test priority pathogens - Ginkgo Bioworks (DNA) and Xwell (XWEL) are expanding their work with the U.S. Centers for Disease Control and Prevention's - CDC's - Traveler-based Genomic Surveillance program to test for more than 30 additional priority pathogens, in addition to SARS-CoV-2. TGS is a flexible, multimodal platform that consists of three complementary approaches of sample collection from arriving international travelers at U.S. airports to enhance early detection of new SARS-CoV-2 variants and other pathogens, and fills gaps in global surveillance. Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks, and XpresCheck by XWELL, are partnering to expand their work with the CDC to monitor more than 30 new viruses, bacteria, and antimicrobial resistance targets including several seasonal respiratory pathogens, such as influenza A and B, RSV, and SARS-CoV-2. The program expansion will launch at four of the program's seven major international airports.

07:11 EST Ecarx delivers ADAS platform to global car manufacturers - ECARX Holdings announced a new series of Advanced Driver Assistance System enabled products, starting with the ECARX Skyland Pro. It will support drivers as the autonomy of their vehicles increases. Delivery of this ECARX ADAS platform has already taken place, with the beginning of its mass production marking a significant milestone for the company. Owing to its dual system-on-chip architecture, ECARX Skyland Pro delivers exceptional performance, and is supported by a sophisticated safety system. Empowered by two Black Sesame Huashan-2 A1000 automotive-grade SoCs that deliver a comprehensive computing power of 116 tera operations per second at 8-bit integer, the high-performance ECARX Skyland Pro enables L2+ advanced driving and parking. The launch of ECARX Skyland Pro will soon be followed by the introduction of ECARX Skyland, a single SoC solution that is able to meet a wider range of OEM needs. Tailored for L2+ ADAS scenarios, ECARX Skyland will allow auto makers to seamlessly combine driving and parking functionalities. Integrating a single Black Sesame Huashan-2 A1000 automotive-grade SoC, ECARX Skyland will enable peak computing power of up to 58 TOPS and support of a 5R6V sensor configuration, to provide more than 20 ADAS feature, including high-speed NoA driving assistance, automated parking assist, and remote parking assist. The mass production of ECARX Skyland Pro and the ECARX Antora 1000 Pro computing platforms has begun as ECARX delivers on its commitment to provide a comprehensive suite of automotive intelligence solutions that seamlessly merge outstanding performance with enhanced security. Through the ECARX Skyland series, car manufacturers will be able to effortlessly integrate cutting-edge ADAS capabilities into their vehicles, ultimately providing safe and efficient driving experiences to a broader audience.

07:09 EST EnCore Energy announces license renewal for South Texas uranium plants - enCore Energy announced the approval of the renewal of the Radioactive Materials License for enCore's combined South Texas In-Situ Recovery Uranium Central Processing Plants at its Rosita, Kingsville Dome, and Vasquez uranium projects. This renewed License was approved by the Executive Director of the Texas Commission on Environmental Quality following an application to allow for the addition of two remote ion exchange units at the Rosita CPP and Wellfield. With the renewal, enCore also expects to be resuming uranium production at its Rosita CPP before the end of November 2023. The uranium bearing ion exchange resin will be processed into yellowcake uranium produced at the Rosita CPP marking the first new uranium production in Texas in over a decade. The 10-year License renewal updates the existing license to conform to new regulatory requirements and current conditions, and it provides enCore with the ability to incorporate additional remote IX operations. enCore Energy is focused on executing production plan in South Texas starting at the Rosita ISR Uranium Central Processing Plant and Wellfield in 2023, to be closely followed by the Alta Mesa CPP and Wellfield in early 2024.

07:06 EST Verastem announces results from avutometinib, defactinib trial at IGCS 2023 - Verastem announced results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer, or LGSOC, following prior systemic therapy. The results of this planned subgroup analysis of Part A of the Phase 2 RAMP 201 trial were presented as a late-breaking abstract in an oral presentation during a plenary session at the annual global meeting of the International Gynecologic Cancer Society, or IGCS 2023, November 5-7 in Seoul, Korea. This planned subgroup analysis was performed to assess efficacy and safety in prior lines of therapy. The analysis also evaluated efficacy in the context of best response to most recent prior treatment in the metastatic/recurrent setting. In the combination arm, the observed ORRs were consistent across patients who received 1-3 and greater than or equal to4 lines of therapy. Prior to enrollment in RAMP 201, only 2/23 patients responded to their last prior treatment in the metastatic/recurrent setting, whereas the combination of avutometinib and defactinib yielded an ORR of 43.5% in this subgroup. The safety profiles of avutometinib and defactinib were similar in the less and more heavily pretreated subgroups and both analyses were consistent with previously reported safety data. The majority of treatment-emergent adverse events were mild to moderate. Initial results of RAMP 201 Part A, presented at the American Society for Clinical Oncology Annual Meeting in May 2023, demonstrated an ORR of 45% and tumor shrinkage in 86% of evaluable patients that were treated with the combination of avutometinib and defactinib. Safety and tolerability were favorable and consistent with previously reported data. As previously announced, Verastem Oncology intends to file for accelerated approval with the FDA for the combination of avutometinib and defactinib based on mature data from the RAMP 201 trial, together with the results of the investigator-initiated FRAME trial. The company plans to initiate its Phase 3 confirmatory trial of avutometinib and defactinib in LGSOC versus standard of care, or SOC, chemotherapy or hormone therapy before the end of the year.

07:03 EST Compugen's COM701 mediates anti-tumor activity in study - Compugen announced data presented at the Annual Meeting of the Society for Immunotherapy of Cancer, held on November 1-5, 2023. The results reinforce previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy. For the first time, initial data showing the association between baseline PVRL2 levels and clinical benefit was presented, suggesting the potential of PVRL2 as a predictive biomarker for clinical benefit in certain indications helping to inform future direction of studies with a biomarker driven strategy. "We were delighted to present at SITC clinical data which reinforces data previously presented, suggesting that COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy", said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. "The clinical benefit shown in patients with platinum resistant ovarian cancer was associated with infiltration of T cells into the tumor microenvironment and independent of baseline inflammatory status, suggesting a COM701 mediated mechanism of action. In addition, we presented data in metastatic breast cancer, another indication in which patients who typically do not respond to immunotherapy, derived clinical benefit from COM701 combinations."

06:56 EST Dish CEO Carlson to resign - In a regulatory filing, DISH Network (DISH) disclosed that on November 3, Mr. W. Erik Carlson notified DISH Network Corporation that he intends to resign as President and Chief Executive Officer effective November 12. Carlson will remain on the board of directors of DISH through the closing of the previously announced merger between DISH and EchoStar Corporation (SATS). "Carlson is not resigning due to any disagreement with the board of directors or management of DISH. DISH intends to work with EchoStar to appoint Mr. Hamid Akhavan, the current Chief Executive Officer and President of EchoStar, to the additional post of President and Chief Executive Officer of DISH effective as of November 13, 2023. Mr. Akhavan's appointment will be subject to the approvals of the DISH board of directors and the EchoStar board of directors. DISH intends to make further disclosure following receipt of such approvals," the filing stated.

06:53 EST NRx, Nephron announce joint agreement to develop intravenous ketamine - NRx Pharmaceuticals and Nephron Pharmaceuticals announced the signing of a development and manufacturing agreement to manufacture a presentation of ketamine suitable for treating suicidal depression. Recent CDC data suggest that more than 3M Americans have active thoughts of suicide and more than 50,000 die from suicide each year.

06:49 EST BigBear.ai to acquire Pangiam for about $70M in an all-stock transaction - BigBear.ai announced a definitive merger agreement to acquire Pangiam Intermediate Holdings, a company in Vision AI for the global trade, travel, and digital identity industries, for approximately $70M in an all-stock transaction. The combined company will create one of the industry's most comprehensive Vision AI portfolios, combining Pangiam's facial recognition and advanced biometrics with BigBear.ai's computer vision capabilities, positioning the company as a foundational leader in one of the fastest growing categories for the application of AI. The proposed acquisition is expected to close in the first quarter of 2024, subject to customary closing conditions, including approval by the holders of a majority of BigBear.ai's outstanding common shares and receipt of regulatory approval.

06:47 EST Freight Technologies CEO issues letter to shareholders - Freight Technologies released an open letter from CEO Javier Selgas addressing concerns regarding recent fluctuations in stock values. Highlights of the letter include: "...In recent times, we've received inquiries about the downward trajectory of our stock...It is my and our management team's opinion that the market's valuation of our stock falls short of our company's actual worth...external factors have continued to exert downward pressure on our stock price...It's important to emphasize our unwavering commitment to success, as exemplified by my and our company CFO's investment in FRGT underlining our steadfast faith in the company...I have also heard concerns about possible illegal transacting on our Ordinary Shares. Rest assured, we will utilize all available means to combat any illicit trading practices affecting our stock, if any. Allow me to share some recent highlights that underscore our commitment to growth: 29% Quarter-over-Quarter Revenue Growth...During this upcoming quarter, we expect an additional quarter/quarter performance with at least an 8% improvement (32% annualized). We will continue to work to make that even higher growth during the final quarter of the calendar year...93% Year-over-Year Margin Increase...We anticipate our third-quarter margins to continue to demonstrate improvement on a y/y and a q/q basis...$9.9M in additional funding secured during 2023...We believe the funding we presently have in place is sufficient to get us to break-even performance on an EBITDA basis before the end of calendar 2024...Coverage from one of the top stock analysts in this space, who continues to publish analyses that include target prices for our Ordinary Shares well above our present trading price...Operational Success:...the successful launch of our LTL offering, which has garnered a positive response from customers and industry experts alike...We have successfully expanded into new markets, creating additional revenue streams and diversifying our customer base, starting operations in El Paso, TX, and increasing the number of lanes going from/to Canada...Sustainability Initiatives...Increased the number of our Fr8Fleet capacity...the establishment of a dedicated Artificial Intelligence department...By harnessing the power of AI, we aim to develop cutting-edge functionalities and tools that will enhance efficiency and internal control, optimize logistics, and unlock unprecedented insights within the supply chain industry...We have completed numerous strategic integrations with GPS providers...Joined AMACARGA:..the expansion of our customer base, which now includes prominent enterprise entities such as Kimberly Clark, Samsung, Whirlpool, Beat Box, and several other industry leaders...We plan to file our six-month financials later this fall and will provide a broad-based update at that time. Javier Selgas, CEO and Board Member".

06:35 EST Hut 8 Mining mined 112 Bitcoin in October - Production highlights for October 2023: 112 Bitcoin were generated, resulting in an average production rate of approximately 3.6 Bitcoin per day. 365 Bitcoin - 66 Bitcoin produced in July, all of August's and September's production, and 85 Bitcoin produced in October - were sold during the month for proceeds totalling C$14.6M (average proceeds per Bitcoin of approximately C$39,980). Total balance of Bitcoin in reserve was 9,113 on October 31 - 7,016 of which were unencumbered. Installed ASIC hashrate capacity at our Alberta facilities was 2.6 EH/s at the end of the month. Hut 8 produced 43.1 BTC/EH in October.

06:33 EST Ault Inc. unit enters license agreement for MLSE technology - Ault Alliance announced that MTIX Ltd., a wholly owned subsidiary of the company's majority owned subsidiary, Avalanche International Corp., has entered into a license agreement for its patented Multiplexed Laser Surface Enhancement technology. The MLSE technology employs several different process algorithms for digital scouring and post-dye cleaning to help reduce and eliminate water from processes that are historically water intensive. Installation of MTIX's technical textile treatment system, which utilizes a proprietary, patented MLSE processing technology, is expected to be completed by year end. Currently, the system is scheduled to undergo final testing, configuration, and training, prior to becoming fully operational during Q1 2024.

06:10 EST Dogness International announces 1-for-20 share consolidation - Dogness International announced that the company's board of directors approved on October 18 to amend its memorandum and articles of association. This amendment will result in a change to the company's authorized shares and par value and effect a share consolidation of the company's issued and outstanding Class A common shares at the ratio of 1-for-20 with the marketplace effective date of November 7.

06:02 EST Liberty Latin America to acquire DISH spectrum assets in Puerto Rico, USVI - Liberty Latin America (LILA) has entered into a definitive agreement with DISH Network (DISH) to acquire DISH spectrum assets in Puerto Rico and the United States Virgin Islands and approximately 120,000 prepaid mobile subscribers in those markets in exchange for cash and international roaming credits. The transaction is subject to certain customary closing conditions, including regulatory approvals, and is expected to close next year. The aggregate asset purchase price of $256M will be paid in four annual installments commencing on the closing date. Liberty Latin America expects to fund the transaction through local liquidity sources, including cash on hand, cash generated from operations, cash generated from asset sales, and/or revolving credit facilities.

05:34 EST UMC reports October revenue NT$19.19M, down 21.17%

05:31 EST NatWest Group, IBM collaborate on generative AI - NatWest (NWG), IBM (IBM) announced enhancements to the bank's virtual assistant, Cora, that will use generative AI to provide customers with access to a wider range of information through conversational interactions. The bank will be among the first in the UK to deploy generative AI with a virtual assistant enabling a safe, intuitive, and accessible experience in its digital services.

05:26 EST Kosmos sees FY23 production 63,000 boepd - Sees FY23 capital expenditures $800M.

05:20 EST China Green receives delisting ltter from NYSE - China Green announced that the company received a notice letter from the New York Stock Exchange, or NYSE, stating that the company will be removed from NYSE's late filers' list to be disseminated to data vendors and will not be posted on the NYSE's listed standards filing status page on www.nyse.com. The NYSE's letter comes after the company filed its delayed annual report on Form 10-K for the period ended June 30, thus becoming current on its financial reporting obligations.

05:10 EST Jacobs wins new contract to support UK nuclear power plants - Jacobs was awarded a new Project Management Resources, or PMR, framework contract with EDF Nuclear Generation, licensee of eight nuclear power stations which account for approximately 16% of the U.K.'s electricity output. Under an existing PMR framework, Jacobs supports operations at four Advanced Gas-cooled Reactor, or AGR, stations; the transition from generation to defueling at another three AGR stations; and the operation and life extension program for the Sizewell B pressurized water reactor. EDF estimates the value of the new two-year contract, which starts on January 1, 2024, at more than $53M.

05:04 EST Kodiak Sciences announces Phase 3 GLOW superiority study met primary endpoint - Kodiak Sciences announced that its Phase 3 GLOW superiority study evaluating tarcocimab tedromer 5 mg in moderately severe to severe NPDR met its one-year primary endpoint. Kodiak paused further development of tarcocimab last summer after its GLEAM and GLIMMER studies in diabetic macular edema did not meet their primary endpoint, in order to evaluate learnings from its pivotal BEACON study in patients with macular edema due to retinal vein occlusion and from its GLOW study. The company believes that the one-year head-to-head BEACON results and primary endpoint and key secondary endpoint GLOW results support the development of three attractive clinical prospects: enhanced tarcocimab ABC, enhanced bispecific KSI-501 ABC, and our KSI-501 bispecific free protein and that Kodiak has on hand sufficient capital to further develop in parallel all three of these prospects.